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Abstract  
Protein glycosylation is a sequential process that involves many enzymes and 
aids in protein stability and cell signalling. Protein glycosylation is altered in 
cancer and can increase its invasive and metastatic potential. Altered 
glycosylation may be due to the hypoxic tumour microenvironment. Hypoxia 
inducible transcription factors (HIFs) orchestrate a shift in cellular metabolism 
towards glycolysis. As glycolytic intermediates are used in protein glycosylation, 
this shift can alter nucleotide sugar availability and potentially alters glycan 
structures. Furthermore, changes in gene transcription in hypoxia may also alter 
glycosylating gene and promote atypical protein glycosylation. Ultimately these 
may alter glycosylated protein function and confer aggressive tumour growth. 
This project aimed to profile changes in glycogene expression in triple negative 
breast cancer (TNBC) where glycogene expression was analysed in tissue 
matched TNBC samples by qPCR using a profiler array. Thirty-two glycogenes 
were upregulated by 2-fold or more. Through qRT-PCR, altered glycogene 
expression was validated in glycogenes of the: GALNT, B3GNT, B4GALT 
families in hypoxic MDA-MB-468 TNBC cells, which replicated the tumour 
environment. Altered glycogene expression was also found in these hypoxic 
cells. Lectin binding analysis on MDA-MB468 cells elucidated that hypoxia 
significantly alters the proportions of sugar residues on the cells. 
Furthermore, it was identified that HIF-1 expression correlated with the 
expression of glycogenes: GALNT3, GALNT6, GALNT7, GALNT12, B3GNT2, 
B4GALT2, B4GALT3, NEU1 and NEU3. SiRNA knockdown of HIF-1 and HIF-
2 in hypoxic MDA-MB-468 cells elucidated suppressed HIF-1 significantly 
altered the expression of B3GNT2, B4GALT3, GALNT6 and GALNT12. 
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Chapter 1: Introduction 
 
1.1: Breast Cancer.  
 
Breast cancer (BrCa) is the most common form of cancer found in women in the 
UK and it is a leading cause of cancer mortality (Breast Cancer Now, 2019).  BrCa 
is a heterogeneous group of neoplasms with different subtypes and 
morphologies. This heterogeneity is well established and serves as the basis for 
clinical outcomes and disease classification (Polyak, 2011). BrCa is broadly 
subcategorised into in situ carcinoma and invasive/infiltrating carcinoma (Stingl 
and Caldas, 2007). Additionally, BrCa subtypes can be distinguished based on 
the presence or absence of hormone receptors. 
Extensive gene expression profiling classifies breast tumours into three subtypes: 
human epidermal growth factor 2 positive (HER2+), luminal and basal like (Sørlie, 
2001). Luminal tumours are positive for oestrogen (ER) and progesterone 
receptors (PR) whereas HER2+ tumours show overexpression of ERBB2, an 
oncogene that can be controlled by anti-HER2 therapies (Hynes, 2016). Triple 
negative breast cancer tumours lack hormone receptors, making them very 
difficult to treat (Lehmann, 2011). 
 
1.1.2: Triple Negative Breast Cancer. 
 
TNBC accounts for approximately 15% of breast cancer and it typically affects 
younger women and those of African American/Hispanic decent (Triple negative 
breast cancer | Cancer Research UK, 2017). TNBC is characteristically a more 
16 
 
aggressive form of BrCa compared to other subtypes (Gonçalves et al., 2018) 
and is associated with a worse patient prognosis. TNBC has a characteristic 
recurrence pattern with the majority of deaths occurring in the first 3 and 5 years 
after initial treatment (Ovcaricek et al., 2011).  TNBCs are highly invasive 
(Ovcaricek et al., 2011), have an accelerated tumour proliferation rate and are of 
high nuclear grade (Jitariu et al., 2017). In general, the higher the nuclear grade 
the more aggressive the tumour cells are due to abnormal cellular nuclei (Jitariu 
et al., 2017). These factors collectively make TNBC particularly aggressive and 
difficult to treat with options limited to surgery in combination with radiation and 
chemotherapy (Park, Ahn and Kim, 2018).  
 
1.2: Protein Glycosylation  
 
Protein glycosylation is post translational modification (PTM) that produces 
glycosidic linkages of saccharides to other saccharides, lipids and proteins 
(Fuster and Esko, 2005).  Glycosylation is one of the most complex and prevalent 
PTM that occurs in eukaryotes, eubacteria and archaea (Lechner and Wieland, 
1989; Messner, 1997). PTMs are covalent and enzymatic proteins modifications 
that occur during or after protein biosynthesis and aid in protein folding, stability 
and cell signalling (Bah and Forman-Kay, 2016). 
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1.2.1: Monosaccharides: the basic structural units of glycans. 
 
Monosaccharides are attached to other monosaccharides via glycosidic linkages 
to form linear or branched structures through an enzymatic process (Varki and 
Sharon, 2009). Glycosidic linkages bond monosaccharides to other residues 
typically through their hydroxyl group; forming  or β linkages (Varki and Sharon, 
2009).  When one or more monosaccharide or oligosaccharide units are 
covalently linked to a non-carbohydrate moiety, a glycoconjugate is formed 
(Varki, Freeze and Manzi, 2009). Glycans (polysaccharides) are simple or 
complex carbohydrate molecules that vary significantly and often encompass a 
substantial amount of the mass of a glycoconjugate molecule (Dwek, 1996). All 
cell types are heavily decorated with varying sugar molecules giving rise to the 
term cell-glycocalyx (Reitsma et al., 2007).  
 
1.2.2: The major glycan classes.  
 
In eukaryotes, the most common classes of glycoconjugates found are defined 
based on the nature of their linkage to the non-glycosyl (aglycone) region (Varki 
et al., 2015). The two main glycan types are described as N- or O- linked-glycans 
in which O-glycosylation is the covalent modification of serine or threonine 
residues in mammalian glycoproteins (Brockhausen, Schachter, & Stanley, 
2009). Currently a consensus sequence for GalNAc addition to polypeptides has 
not been determined (Bapu et al., 2016). N-linked glycosylations occur when a 
sugar moiety, most often N-acetylglucosamine (GlcNAc), is attached to an 
18 
 
asparagine residue of a polypeptide, in the consensus sequence Asn-x-ser/Thr, 
where X is any amino acid except for proline  (Varki and Sharon, 2009).  
 
1.3: O-Linked Glycosylation.  
 
O-glycosylation is initiated when an -linked N-acetylgalactosamine (O-GalNAc) 
residue becomes linked to a serine or threonine amino acid in the Golgi apparatus 
(Brockhausen, Schachter, & Stanley, 2009). This structure can be extended with 
a number of sugars including galactose, N-acetylglucosamine (GlcNAc), fucose 
or sialic acid through a highly regulated and sequential process (Yamashita et al., 
1995) (Figure 1.1).  
There are four common forms of O-glycans: cores 1-4 (Brockhausen, Schachter 
and Stanley, 2009) (Figure 1.1). These structures are often branched, resulting 
in a highly variable population of sugars (Brockhausen, Schachter and Stanley, 
2009). Many of the sugar molecules on mucin type O-glycans are antigenic, for 
example: the T antigen (also known as Core 1) (Brockhausen, Schachter and 
Stanley, 2009). T antigen is cancer specific and is made up of short O-GalNAc 
residues but can also carry sialic acid and form sialyl-T antigens (Tian and Ten 
Hagen, 2009) (Figure 1.1).  
Core 2 structures are formed by the addition of β1-6 GalNac to core 1 structures; 
core 3 structures are less common and are synthesised when a β1-3 GlcNAc is 
added to O-GalNAc (Brockhausen et al., 2009) (Figure 1.1). Core 4 is a simple 
extension of core 3 O-Glycans in which another GlcNAc residue is connected via 
a β1-6 linkage (Corfield and Berry, 2015) (Figure 1.1).  
19 
 
 
 
Figure 1.1: Mucin-type core structures and their decoration. Representative 
examples of core 1, 2, 3 and 4 extended O-glycans composed of N-
acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc) and galactose 
(Gal) residues. All four cores can be subject to branching, extension and can be 
terminated by sialic acid and fucose (Fuc) residues (Brockhausen, Schachter and 
Stanley, 2009).  
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1.3.1: O-linked glycosylation initiation: The GALNT family.  
 
O-glycosylation is initiated by a group of polypeptide glycosyltransferases with 
the prefix GALNT. The GALNT family is made up of approximately 21 enzymes 
encoded by different genes (Brockhausen et al., 2009). Little is known about 
these enzymes however, it has been proposed that glycosylated mucin domains 
are created by the action of several of the GALNT enzymes, in a hierarchical and 
successive process (Pratt et al., 2004). Twelve mammalian isoforms for GALNT 
enzymes exist including GALNT1-13 (Ten Hagen, Fritz and Tabak, 2003). The 
distribution of these enzymes in adult tissues is discrete. Some isoforms are 
found in a number of tissues i.e. GALNT1 and GALNT2 and act upon a large 
range of substrates (Ten Hagen, Fritz and Tabak, 2003) while others are more 
specific in their substrate specificity and expression (GALNT5, GALNT7, 
GALNT10 and GALNT11)  (Hagen et al., 2003).  
Pratt et al., (2004) proposed that GALNT1, 2 and 5 represent the first level of O-
linked glycosylation as their enzymatic activity occurs early in the O-glycosylation 
process. These enzymes prefer non- and -monoglycosylated peptide substrates 
which coincides with the fact that their activity is inhibited by steric inhibition due 
to glycosylation of the neighbouring Ser/Thr residue (Gerken et al., 2002). It was 
suggested that GALNT3 and GALNT4 represent the intermediate level of O-
linked glycosylation and prefer di-glycosylated peptides (Pratt et al., 2004). 
Furthermore, GALNT10 may facilitate the completion of mucin-domain assembly 
and contribute to the highly glycosylated glycans found in vivo. 
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1.4: N-linked glycosylation 
 
N-linked glycosylation is one of the most important and chemically complex PTMs 
in all eukaryotes (Stanley, Taniguchi and Aebi, 2015). N-glycan synthesis occurs 
in a two-phased process in the endoplasmic reticulum and Golgi apparatus (Aebi, 
2013). N-linked oligosaccharides share a common core GlcNAc2Man3 structure 
and synthesis begins on the cytoplasmic side of the ER membrane. Transfer of 
GlcNAc-P from UDP-GlcNAc to dolichol phosphate, a lipid like precursor, 
generates dolichol pyrophosphate N-acetylglucosamine (Dol-P-P-GlcNAc) 
(Chang et al., 2015). Fourteen sugar residues are added to Dol-P and the entire 
glycan is then transferred “en bloc” to an Asn-x-Ser/Thr sequon in a protein 
(Stanley, Schachter, & Taniguchi, 2009). The N-glycan is modified further via 
hydrolytic removal of sugar residues by highly specific -glycosidases and -
mannosidases that remove terminal glucose and mannose, respectively 
(Liebminger et al., 2011). EDEMs (endoplasmic reticulum degradation-enhancing 
-mannosidases like proteins) are also involved in early N-glycan processing, 
where they recognise and target misfolded proteins for ER degradation (Olivari 
and Molinari, 2007). These initial trimming steps are conserved among 
eukaryotes and regulate glycoprotein folding though endoplasmic reticulum 
chaperone interactions that recognise specific features of the shortened glycan 
(Stanley, Schachter and Taniguchi, 2009).  
After trimming, the glycan is re-glycosylated with other sugars including 
galactose, fucose and sialic acid (Bieberich, 2014) (Figure 1.2). The final product 
of early N-glycan processing is Man5GlcNAc2, which is used as an acceptor 
substrate by GNT1 for the transfer of a single GlcNAc residue (Strasser et al., 
1999). Without the activity of GNT1, enzymes such as GM2, GNT2, XYLT, FUT11 
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and FUT12 cannot function and formation of complex glycans is inhibited. In the 
event of premature truncation, the N-glycan cannot undergo further remodelling 
to form a complex or hybrid structure.  
In the trans-Golgi, the final N-glycan modifications occur. GALT1 and FUT13 
synthesise Lewis--trisaccharide complexes on N-glycans (Strasser et al., 2007). 
This Lewis epitope is highly expressed in the developing brain and is involved in 
cell-cell interactions (Yaji et al., 2015).  
 
 
 
Figure 1.2: Biosynthesis of N-glycans within the Golgi Apparatus.  Glycans 
are trimmed and extended in the Golgi apparatus. Glycotransferases use 
nucleotide sugars as extension reaction donors (adapted from Bieberich, 2014). 
Symbols used to represent sugar molecules are indicated in the key. Man: 
Mannose, GlcNAc: N-acetylglucosamine, Fuc: Fucose, Gal: Galactose.  
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1.4.1: N-glycan subtypes. 
 
N-glycans are divided into three types: complex, hybrid and high mannose 
(Figure 1.3). In general, N-glycans are heterogeneous and this structural diversity 
is called glycoform (Nagasaki et al., 2016). High mannose glycans comprise a 
glycan in which only mannose residues are attached to the core (Figure 1.3). 
Complex N-glycans contain outer chains with sialic acid, galactose, GalNAc and 
-linked mannose residues (Tabas, Schlesinger and Kornfeld, 1978) (Figure 1.3). 
Hybrid N-glycans have two branches from the core, one of which terminates in 
mannose and the other which terminates with a complex sugar (Yamashita, 
Tachibana and Kobata, 1978) (Figure 1.3).  
 
Figure 1.3: N-glycan structural subtypes. Three forms of N-glycans exist 
including high mannose (man), hybrid and complex type N-glycans. All three 
structures share a common core structure of di-N-acetylglucosamine tri-mannose 
linked to an asparagine.  Sugars are indicated in the key. Adapted from (Higel et 
al., 2016).  
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 1.5: The biological role of glycans. 
 
The functional role of biological glycans is divided into three comprehensive 
categories: modulatory and structural properties, extrinsic recognition and 
intrinsic recognition (Varki and Lowe, 2009). Extrinsic glycan binding proteins 
(GBPs) are composed of pathogenic microbial adhesins, agglutinins or toxins, 
whereas intrinsic GBPs mediate cell-cell interactions or facilitate in the 
recognition of extracellular molecules (Varki and Lowe, 2009). Processes 
including cell development, immunity, and cancer invasion are regulated by 
glycans (Imai et al., 1990; Solá and Griebenow, 2009; Zhou et al., 2014).  For 
example, the ability to swallow food is facilitated by lubricating glycans (Maytin, 
2016), and the signalling properties of proteins attached to glycans can affect 
transforming growth factor (TGF) signalling - which aids in normal lung 
development (Wang et al., 2005). In terms of immune recognition, heavily 
glycosylated cells can evade loading onto the major histocompatibility complex 
of immune B cells, as peptide loading is disrupted. This mechanism of immune 
evasion is often used by enveloped viruses, which are heavily glycosylated (Wang 
et al., 2009). N-glycan structure can also influence the function and dynamics of 
glycoproteins. Removal of non-reducing end sugars and linking of sialic acid to 
the galactose 3-OH or 6-OH position of a complex N-glycans significantly affects 
glycoprotein distribution (Ogura et al., 2016). One of the major modification of 
complex N-glycans includes the linkage of a fucose residue to the reducing end 
GlcNAc (Becker and Lowe, 2003). The transfer of fucose to complex N-glycans 
is facilitated by fucosyl transferase 8 (FUT8) which forms an 1-6 fucosyl linkage 
and has been shown to play an important role in cell growth, cell survival and cell 
mediated cytotoxicity (Wang et al., 2005; Tomita et al., 2012).  Moreover, core 
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fucosylation has been implicated in the pathophysiological steps involved in 
carcinogenesis and tumour progression (Moriwaki and Miyoshi, 2010).  
 
1.6: Cancer and glycosylation. 
 
Altered glycosylation is a hallmark feature of cancer cells and the expression of 
specific glycans are known to be distinguished markers of tumour progression 
(Varki et al., 2015). Tumour cells show numerous glycosylation alterations 
compared to healthy tissue, which results in a  heterogeneous cell population 
(Pinho & Reis, 2015). The most common cancer-associated changes to cell 
glycosylation include sialylation, fucosylation, O-glycan truncation, and N- and O-
linked glycan branching (Hakomori, 2002; Pinho & Reis, 2015). According to the 
hallmarks of cancer’ proposed by Hanahan and Weinberg in 2011, avoiding 
immune surveillance, activating invasion, metastasis and deregulated cellular 
energetics are classical strategies of cancer progression (Hanahan and 
Weinberg, 2011). The ways which altered protein glycosylation facilitates these 
mechanisms under malignancy has been well-documented. Changes to protein 
glycosylation in cancer can lead to steric inhibition of adhesion molecules such 
as cadherins and integrins, which can promote cell displacement and initiation of 
metastasis (Varki et al., 2015).  
The Tn antigen is highly expressed in 90% of breast carcinomas (Prokop and 
Uhlenbruck, 1969), and in 10-90% of bladder, cervix, colon, lung, stomach, ovary 
and prostate carcinomas (Desai, 2000).  Despite its abundant presence in cancer, 
the role of the Tn antigen in cancer development remains unclear (Fu et al., 
2016). However, the Tn antigen has been strongly tied to the metastatic potential 
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of a number of cancers including breast, gastric, and cervical (Fu et al., 2016) 
and furthermore, its expression has been implicated in tumour 
immunosurveillance (Ju et al., 2013). 
Hakomori & Kannagi (1983) first described the two main mechanisms which 
promote tumour-associated alterations of carbohydrate structures. They 
postulated that incomplete synthesis of glycans occurs more often in early 
carcinogenesis, and subsequently inhibits the normal synthesis of complex 
glycans that are found in healthy tissues (Hakomori and Kannagi, 1983). By 
contrast, the theory of neo-synthesis was proposed, in which in advanced stages 
of cancer, sialyl Lewis X and sialyl Lewis A (cancer associated glycans) are 
induced by the malignancy itself. A shift from the classical glycosylation pathway 
occurs in cancer cells and inevitably leads to altered glycan expression. This 
change in glycan structures and expression is owed to a number of factors 
including altered expression (increase or decrease) of glycosylation enzymes 
including glycosyltransferases and the availability of nucleotide sugars (Pinho & 
Reis, 2015). The expression and activity of glycosidase’s and 
glycosyltransferases have a large impact on the distribution and abundance of 
glycans (Doherty et al., 2018). Interestingly, it has also been suggested that the 
intra-environment of the Golgi apparatus may promote aberrant glycosylation 
through changes in pH and structural organisation of the apparatus itself 
(Kellokumpu, Sormunen and Kellokumpu, 2002).  
 
1.6.1: Altered glycosylation and TNBC. 
 
Altered protein glycosylation is common is a number of cancers including 90% of 
BrCa (Hanahan and Weinberg, 2011; Zhou et al., 2014; Chen et al., 2016).  
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Aberrant expression of glycans has been seen in a high percentage of breast 
cancers and frequently presents as the loss of core glycan structures and the 
expression of tumour-associated antigen markers (Springer, 1984; Burchell, 
Mungul and Taylor-Papadimitriou, 2001). In TNBC, 72 differentially expressed 
glycoproteins have been identified, most notably: Vascular endothelial growth 
factor receptor 1, Insulin receptor and Tissue factor pathway inhibitor (Chen et 
al., 2016).  However, little is known about how altered glycosylation is influenced 
by the hypoxic tumour environment and how this promotes aggressive tumour 
growth in TNBC.  
 
1.7: Hypoxia. 
 
Hypoxia (pO2 < 10 mmHg) is defined as the failure of oxygenation at the tissue 
level (Samuel and Franklin, 2008) and it is found in pathophysiological conditions 
including: atherosclerosis, sleep apnoea, mountain sickness, ischemic disease 
and many cancers (Li et al., 2006; Brahimi-Horn and Pouysségur, 2007; Brahimi-
Horn, Chiche and Pouysségur, 2007). In solid tumours, hypoxia is common due 
to uncontrolled cell proliferation in the absence of efficient vascularisation 
(Semenza, 2013). Due to unlimited proliferation of tumour cells, increased 
oxygen consumption is observed as Intratumoural hypoxia develops and the cells 
outstrip their blood supply (Koh, Spivak-Kroizman and Powis, 2010).  
Hypoxia promotes an imbalance between pro- and anti-angiogenic factor 
production, which induces rapid and enhanced chaotic blood vessel formation 
(Conway, Collen and Carmeliet, 2001). In tumours, new blood vessels are often 
abnormal and prone to leakage and collapse which causes local hypoxia. The 
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formation of new blood vessels in tumour tissue increases blood and oxygen 
supply for continuous tumour growth (Carmeliet and Jain, 2000). However, the 
ever-growing tumour ultimately outgrows its blood supply and causes further 
tumoral hypoxia which stimulates additional angiogenesis, in a vicious cycle. 
Enhanced angiogenesis is linked to cancer metastasis due to improved 
extravasation, circulation and the movement of tumour cells to better 
vascularised normoxic tissues (Carmeliet and Jain, 2011).  
The hypoxic tumour environment creates a particularly hostile environment which 
is subject to decreased respiration, increased glycolysis, low pH due to increased 
lactate production and compromised ATP production (Eales, Hollinshead and 
Tennant, 2016; San-Millán and Brooks, 2016; Sgarbi et al., 2018). In healthy 
cells, oxidative phosphorylation is the mechanism for adenosine triphosphate 
(ATP) production however in tumours, pyruvate is converted into lactate as 
opposed to entering the tricarboxylic acid cycle (TCA), through aerobic glycolysis. 
This is called the Warburg effect (Figure 1.4) (Warburg, Wind and Negelein, 
1927). This lactate acid production occurs at a rate 40 times higher than normal 
cells (Holm et al., 1995) and results in a highly acidic tumour microenvironment. 
This promotes tumour metastasis and treatment resistance, partly because of 
increased cell detachment (Neri and Supuran, 2011) (Figure 1.4). As a result, 
tumour cells promote adaptive responses to match O2 supply with bioenergetic, 
metabolic and redox demands.  
Intratumoural hypoxia is commonly found in breast cancer and is strongly 
associated with a significantly increased rate of metastasis and patient mortality 
(Semenza, 2016). TNBC is inherently hypoxic due to poor vascularisation as 
shown by overexpression of hypoxia-inducible factor 1- (HIF-1) (Semenza, 
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2013) and a median partial oxygen pressure of 10 mmHg compared to 65 mmHg 
found in healthy breast tissue. The activation of hypoxia inducible factors (HIFs) 
drives expression of a battery of genes and promotes a toxic tumour 
microenvironment which facilitates aggressive tumour growth (Gilkes and 
Semenza, 2013).  
 
Figure 1.4: The metabolic shift in cancer. (A) To facilitate tumour growth, 
cancer cells promote uptake of glucose and increase lactate production (aerobic 
glycolysis) compared to healthy cells. This creates an acidic tumour environment 
which increases tumour metastasis and invasion. (B) Healthy cells favour the 
energy efficient oxidative phosphorylation mechanism for ATP production which 
creates a small proportion of lactate.  
 
1.7.1: Hypoxia inducible factors (HIFs).  
 
Hypoxia-inducible factors’ (HIFs) play a crucial role in the adaptive response to 
reduction in oxygen availability and drive the expression of many genes involved 
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in glucose metabolism, cell proliferation and angiogenesis (Annibaldi and 
Widmann, 2010). HIF transcription factors are composed of a stable constitutively 
expressed β-subunit and oxygen-liable HIF-1, HIF-2 or HIF-3 subunit 
(Dengler, Galbraith and Espinosa, 2014) (Figure 1.5). The stability of the oxygen-
liable subunit is controlled through hydroxylation by prolyl hydroxylases (PHDs) 
and subsequent ubiquitination (Maxwell, 1999).  
Under normal physiological conditions, prolines 402 and 564 are hydroxylated by 
prolyl hydroxylases (PHD) (Kanaya and Kamitani, 2003) which targets HIF- for 
degradation by the proteasome through binding of the E3 ligase, the von Hippel-
Lindau protein (VHL) (Semenza, 2001). In hypoxic conditions, the HIF- subunit 
becomes stabilised (Henze and Acker, 2017) due to the low affinity of oxygen to 
the PHDs (Chan et al., 2005) (Figure 1.5). Decreased PHD activity decreases 
hydroxylation which inhibits the binding of the VHL to the HIF- subunit. This 
causes stabilisation of the HIF complex (Figure 1.5) (Chan et al., 2005).   
Once stable, HIF complex translocates to the nucleus, where hypoxia-responsive 
genes are transactivated though binding to hypoxia response elements located 
in the promoter or enhancer regions of hypoxia-inducible genes (Dengler, 
Galbraith and Espinosa, 2014) (Figure 1.5). The stabilized HIF-1α subunit 
translocates to the nucleus, dimerizes with ARNT, and transactivates hypoxia-
responsive genes through binding to hypoxia response elements (HREs) located 
in the promoter or enhancer regions of hypoxia-inducible genes 
In excessively proliferating tumour tissue, oxygen demand is outstripped by 
supply which creates a toxic hypoxic milieu (Thomlinson and Gray, 1955). As a 
result of the adaptation to the hypoxic tumour environment, HIFs can promote 
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several avenues of aggressive tumour growth including metastasis, invasiveness 
and chemoresistance (Kim and Lee, 2017).  
 
 
Figure 1.5: Representative schematic diagram of the impact of hypoxia on 
HIF- subunit stability. The mechanism by which the transcription factors HIF-
1 and HIF-2 respond to normoxia (A) and hypoxia (B). Under normoxic 
conditions HIF is hydroxylated and targeted for degradation by the proteasome. 
In hypoxic conditions HIF accumulates, binds to HIF-1β, which binds to the 
hypoxia response unit and leads to overexpression of HIF proteins. PHD: Prolyl-
hydroxylase. VHL: von Hippel-Lindau factor.   
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1.7.2: HIF-1. 
 
HIF-1 plays a vital role in tumour adaptation to changes in O2 concentration 
through the transcriptional regulation of over 100 downstream genes (Semenza, 
2001), including glucose metabolism (GLUT1 and GLUT3), cell proliferation (C-
MYC), migration and angiogenesis (VEGF) genes (Masoud and Li, 2015). In 
growing tumour tissue, HIF-1 facilitates the shift from oxidative phosphorylation 
to aerobic glycolysis in order to maintain energy production (Warburg Effect) 
(Warburg et al., 1956) (Figure 1.4). As a result, hypoxic cells metabolise an 
increased quantity of glucose in order to meet their energy needs. HIF-1 
mediates this metabolic conversion partly through the expression of glucose 
transporters GLUT1 and GLUT3 as well as the upregulation of glycolytic enzymes 
(Denko, 2008). These transporters promote the influx of glucose into the hypoxic 
cell driving glycolysis and anaerobic metabolism (Seeber et al., 2010). 
HIF-1 mRNA is produced relatively constantly in TNBC cells and shows a 
marked increase in expression under hypoxia (Galbán and Gorospe, 2009). In 
TNBC, increased expression of HIF-1 is thought to contribute to tumour 
progression through a number of factors (Gilkes and Semenza, 2013). HIF-1 
promotes the expression of CA9; a gene widely expressed in response to hypoxia 
(van den Beucken et al., 2009). CA9 regulates intracellular pH balance and 
facilitates the adaptation of malignant cells to extracellular milieu toxicity (Benej, 
Pastorekova and Pastorek, 2014). In the hypoxic tumour regions, CA9 
participates in bicarbonate transport (Ditte et al., 2011) by catalysing hydration of 
pericellular CO2, and therefore local production of bicarbonate ions are readily 
available for influx by transporters (Ditte et al., 2011). As a result, protons as a 
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by-product of CO2 hydration remain in the pericellular space and reduce the pH 
of the environment. This promotes tumour cell invasion (Ditte et al., 2011) through 
stimulation of migratory pathways (Benej, Pastorekova and Pastorek, 2014). 
 
1.7.3: HIF-2. 
 
HIF-1 and HIF-2 subunits are structurally similar, sharing 83 and 70% 
sequence identities in their DNA binding and dimerization domains, respectively 
(Hu et al., 2007). However, they differ in their transactivation domains and may 
regulate different batteries of genes (Hu et al., 2007). Interestingly, target gene 
selectivity is not determined by the bHLH DNA-binding domains. Alternatively, 
the N-TADs appear to contribute to target gene selectivity. HIF-1 and HIF-2 
bind to the same hypoxia response element (HRE) consensus sequence: ‘5-
(A/G)CGTG-3’ (Mole et al., 2009).  
HIF-2 expression has been reported to be restricted to endothelial cells, lung 
type II pneumocytes, liver parenchyma, interstitial cells of the kidney (Wiesener 
et al., 2003; Keith, Johnson and Simon, 2012) and breast cancer cell lines. HIF-
2 expression is a part of the normal physiological response to hypoxia (Loboda, 
Jozkowicz and Dulak, 2010) however, cancer cells show increased expression of 
HIF-2 to promote tumour growth and metastasis. HIF-2 activation of target 
genes such as VEGF, promotes tumour growth through mechanisms such as 
increased angiogenesis. In later stages of BrCa, HIF-2 expression is associated 
with a more aggressive BrCa phenotype (Holmquist-Mengelbier et al., 2006), 
poor patient outcome and an increased rate of distant tumour reoccurrence 
(Helczynska et al., 2008).  
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In TNBC, HIF-2 is thought to contribute to tumour angiogenesis, growth and cell 
proliferation through expression of genes such as erythropoietin (EPO). EPO has 
been shown to activate extracellular signal-related kinase (ERK) and promote 
migration in MCF-7 breast cancer cells (Lester et al., 2005). Similarly, positive 
immunohistochemical expression of the HIF-2 target, vimentin, is associated 
with high-grade tumours and increased tumour proliferation in breast cancer 
(Hemalatha, Suresh and Harendra Kumar, 2013). 
 
1.8: Hypoxia and altered glycosylation in cancer.  
 
Hypoxia in tumours has been linked to aggressive phenotypes and treatment 
failure  (Generali et al., 2006; Bos et al., 2009). HIF transcription factors activate 
genes involved in the tumour response to hypoxia, including those involved in 
angiogenesis (VEGF) and glucose transport (GLUT1/3). Hypoxia causes altered 
metabolism (López-Barneo, Pardal and Ortega-Sáenz, 2001), in which GLUT1 
and GLUT3 caused increased glucose consumption to compensate for the high 
metabolic demand of tumour growth (Cheng et al., 2006). The shift in metabolism 
due to hypoxia also alters the expression of glycolytic enzymes which suggests 
that hypoxia plays a critical role in regulation of nucleotide sugar biosynthesis 
pathways (Stanley, Taniguchi and Aebi, 2015).  
 
1.9: Overall aims and research questions. 
 
The overall aim of this project was to uncover changes that occur to the 
glycosylation profile of TNBC as a result of hypoxic adaptation. This included 
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alterations to glycogene expression and sugar residues proportions on the cell 
surface. Furthermore, it was aimed to assess the role of hypoxia inducible factors 
HIF-1 and HIF-2 in regulating glycogene expression in TNBC. In doing so, a 
greater understanding of the cellular glycome of TNBC has been gathered. 
Understanding the mechanisms involved in altered glycogene expression in 
TNBC and how this affects cell surface glycans is crucial to the development of 
novel drug targets to treat this particularly aggressive form of breast cancer. 
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Chapter 2: Materials and Methods 
 
2.1: Reagents and chemicals.  
 
All reagents and chemicals were obtained from Sigma-Aldrich (Gillinham, UK), 
ThermoFisher Scientific (Paisley, UK), VWR Chemicals (Leicestershire, UK) or 
Qiagen (Manchester, UK) unless otherwise stated. 
 
2.2: TNBC RNA samples and Tissue Matched Controls. 
 
Three TNBC samples (T) and three tissue matched controls (N) were obtained 
the Tayside Biorepository (Dundee University): Tumour 11004T, matched control 
11004N, Tumour 10046T, matched control 10046N, Tumour 10076T and 
matched control 10076N. The RNA integrity number (RIN) and concentration of 
RNA in each sample was pre-determined by Dr Susan Bray at the Tayside Tissue 
Bank (Table 2.1).  
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Table 2.1: The integrity (RIN) and concentration of TNBC RNA obtained from 
the Tayside Biorepository. 
Sample RIN Value Concentration (ng/µL) 
11004T 6.6 458 
11004N 5.5 26 
10046T 3.1 54 
10046N 5.5 36 
10076T* 5.0 408 
10076N* 2.7 47 
*Samples not used for RT2 Human Glycosylation Array. 
 
Table 2.1.1: Pathological examination of tumour samples.  
Tumour 
Identifier 
11004 10046 10076 
Tumour grade 3 2 3 
Greatest tumour 
dimension 
5cm 5cm 
Extension to the 
chest wall 
Number of 
lymph node 
metastasis 
1-3 1-3 10+ 
qRT-PCR array 
profiler 
analysis? (Y/N) 
Y Y N 
Additional 
comments 
N/A N\A peau d'orange 
 
2.3: MDA-MB-468 cells. 
 
MDA-MB-468 triple negative breast cancer cells were gifted from Dr Lisa Pang, 
The Roslin Institute, The University of Edinburgh at passage number 6. MDA-
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MB-468 cells were cultured in 75 mL flasks (T75) in complete medium: 
Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Thermofisher Scientific, UK) 
supplemented with 10% heat-inactivated foetal bovine serum (FBS) (Invivogen) 
and 1% Penicillin-Streptomycin (P/S) (Invivogen) at 37°C, with 5% CO2 in high 
humidity. All cell culture work was performed in sterile laminar flow hood.  
 
2.3.1: Passaging cells. 
 
Media was aspirated and cells were washed with 0.9% sterile saline solution 
(Baxter). Approximately 2mL of 1 X Trypsin (Bioline)was added to cover the 
monolayer of cells. Cells were incubated at 37°C for approximately 5 minutes.  
The trypsin was neutralised by the addition of 8 mL of complete media and the 
cells were detached by gentle pipetting. Cell suspension was transferred to a 15 
mL falcon tube and the cells collected by centrifugation at 238xg for 5 minutes at 
room temperature in a Universal 320 centrifuge (Hettich Zentrifugen). The pellet 
was resuspended in 10 mL of complete media. Cells were seeded at dilutions 
ranging between 1:10 and 1:4 into a new T75 flask (Corning, Wiesbaden, 
Germany).  
 
2.3.2: Cryopreservation of cell lines.   
 
Cells were grown to ~80% confluency (as described in section 2.3) in a T75 flask 
and trypsinised (see section 2.3.1). They were transferred into a 15 mL falcon 
tube and collected by centrifugation at room temperature at 238xg for 5 minutes.  
The pellet was resuspended in 10 mL of complete media. Freezing media (80% 
39 
 
FBS, 20% DMSO) (Invivogen, VWR Chemicals) was added to the cells at a ratio 
of 1:1 mL and 0.5 mL of the cells transferred to a cryotube (Simport, Beloeil, 
Canada, PK/100). After 24 hours in an isopropanol bath (Mr. Frosty™ Freezing 
Container, Thermofisher Scientific, UK) at −80°C, the vials were transferred to 
liquid nitrogen (−196°C) for long term storage.   
To recover cells after freezing, cells were resuspended in 10 mL of warm fresh 
complete medium before centrifugation at 238xg for 5 minutes. The cell pellet 
was resuspended in 10 mL fresh media, transferred to a new flask and incubated 
at 37°C in 5% CO2.  
 
2.4: Cell Counting. 
 
Cell number was estimated using a Neubauer haemocytometer (Marienfeld, 
Lauda, Konigshofen, Germany). After passaging the cells (section 2.3.1), 10 µL 
of cell suspension was added onto the haemocytometer. One 5x5 grid on the 
haemocytometer was counted in duplicate and the number of cells averaged. 
Non-viable cells were not included in this count. This number was multiplied by 
104, giving the total number of cells/mL.  
 
2.5: Experimental hypoxia. 
 
Acute hypoxia was induced in MDA-MB-468 TNBC cells at approximately 60% 
confluency. Immediately before induction of hypoxia, cells were supplemented 
with fresh complete media. The flasks were placed in a modular hypoxia chamber 
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(Billups-Rothenberg, Inc. Del Mar, CA, USA) and hypoxia was induced following 
methods of Wu & Yotnda (2011). The chamber was sealed and flushed with 1% 
O2 gas mixture (1% O2, 5% CO2 and 94% N2 gas: Cat: 2052055, BOC), at a flow 
rate of 20L/ min for 10 minutes. The sealed chamber was incubated at 37°C with 
5% CO2 in a standard incubator.  After 1 hour, the chamber was removed from 
the incubator and flushed 1% O2 as above and placed back into the incubator for 
a further 21 hours, totalling 22 hours of hypoxic exposure. 
 
2.6: Lectin staining. 
 
Biotinylated lectins and phycoerythrin-conjugated streptavidin (PE-Strep) were 
obtained from Vector Laboratories (Burlingame, CA, USA) and were used to stain 
cells (Table 2.2). Lectins (5 μg /mL) were added to each fluorescence-activated 
cell sorting (FACS) tube containing approximately 2.5x105 cells and incubated on 
ice for 45 minutes. The cells were centrifuged to collect at 238xg for 5 minutes at 
4°C and resuspended in 2 mL of ice-cold PBS. This was repeated three times. 
PE-Steptavadin was diluted to 1 μg/mL in PBS and 100 μL added to each tube 
which was incubated in the dark for 15 minutes. The cells were washed as above 
and resuspended in 150 μL PBS and analysed by flow cytometry counting 10000 
gated events (FACSCalibur, Becton Dickinson Bio-sciences).  
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Table 2.2: Lectins used in this study. 
Lectin Name Abbreviation Binding target 
Dolichos Biflorus 
Agglutinin 
DBA 
N-acetyl-galactosamine 
(Ogino et al., 1999) 
Lens Culinaris Agglutinin LCA 
α-mannose on N-linked 
glycans (Kornfeld et al., 
1981) 
Peanut Agglutinin PNA 
N-acetyl-galactosamine, 
galactose (Mérant et al., 
2005) 
Phaseolus Vulgaris 
Erythroagglutinin 
PHA-E 
Complex type N-glycans 
(Cummings and Etzler, 
2009) 
Ricinius Communis 
Agglutinin 
RCA 
Terminal β-D-galactose 
(Itakura et al., 2007) 
Wheat Germ Agglutinin WGA 
N-acetyl-neuraminic acid 
(Kuno et al., 2005) 
 
2.7: siRNA Transfection  
 
Known-target sequence control small interfering RNAs (siRNA) (1027310), HIF-
1 (SI02664053) and HIF-2 (EPAS1) (SI00380212) FlexiTube siRNAs (Qiagen) 
were resuspended in 1 mL RNase free dH2O to obtain a 20 µM stock 
concentration.  
MDA-MB-468 cells were seeded at a density of 3.5x105/ mL in 6 well dishes. This 
achieved 60% confluency after 24 hours of incubation at 37°C in high humidity. 
SiRNAs (50nM) were diluted in 100µL OptiMEM media (Gibco) and 12 µL 
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HighPerfect transfection reagent before vortexing to mix and incubating for 10 
minutes at room temperature. Controls included FlexiTube non-targeting siRNAs 
and a HighPerfect Tranfection Reagent only. The transfected cells were 
incubated for 24 hours at 37°C in high humidity. After incubation, the media was 
aspirated and replaced with complete medium and cells were exposed to acute 
hypoxia (1% O2) for 22 hours (as in section 2.5). Cells were harvested and stored 
at -80°C for later analysis.  
The degree of knockdown following siRNA transfection was assessed using 
ImageJ software (v. 1.8.0_112). ImageJ was used to analyse the jpeg image of 
individual immunoblots which were exported from the LI-COR Odyssey imaging 
system (Odyssey-3074, LI-COR, Cambridge, UK) and Odyssey Image Studio 
v2.0 software (ThermoFisher Scientific, UK). The pixel density of the background, 
control and siRNA were determined dividing the image density of the loading 
control versus the protein of interest where the control was taken to equal 1.    
 
Table 2.3: SiRNA molecules used in this study. 
Target Gene Cat.No Sense/Anti-Sense Sequences 
HIF-1 SI02664053 S:GAAGAACUAUGAACAUAAATT
 
AS:UUUAUGUUCAUAGUUCUUCCT 
HIF-2 SI00380212 
S:CGGCGUCUGAACGUCUCAATT 
AS:UUGAGACGUUCAGACGCCGAG 
Non-targeting 
scrambled 
1027310 
S:UUCUCCGAACGUGUCACG 
AS:ACGUGACACGUUCGGACA 
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2.8: RNA extraction and analysis. 
 
Cells were washed with PBS and then harvested on ice by scraping into ice cold 
PBS solution. MDA-MB-468 cells were collected by centrifugation (5415R, 
Eppendorf, Stevenage, UK) at 3000xg at 4°C for 5 minutes, before discarding the 
supernatant. RNA was extracted from pelleted cells with TRIsure reagent 
(Bioline) following the manufacturer’s instructions. Briefly, 1 mL of TRIsure was 
added per cell pellet which was disrupted by pipetting. RNA was separated from 
the organic phase and interphase by addition of 200 μL chloroform, vigorous 
shaking by hand for 15 seconds and centrifuging at 12000xg (5415R, Eppendorf) 
for 15 minutes at 4°C. RNA was precipitated by adding 0.5 mL ice cold 
isopropanol incubating for 10 minutes on ice and centrifuging for 10 minutes at 
12000xg at 4°C. Cell pellets were washed with 1 mL 75% ethanol air-dried at 
room temperature and resuspended in RNase-free water.  
 
2.9: Determining the integrity and purity of extracted RNA. 
 
The concentration of RNA was estimated by diluting samples with dH2O (1:5) and 
1 µL was estimated via Nanodrop (Nanodrop 2000, Thermofisher). The purity and 
integrity of extracted RNA was assessed by fluorescence using the Agilent 2100 
Bioanalyser (Aglient Technologies Ltd., Stockport, UK) and the Bioanalyser 2100 
Expert Software. All samples were prepared according to the manufacturer’s 
instructions using the Agilent RNA600 Nano Kit (Agilent Technologies Ltd, 5067-
1522). Each sample was analysed on an RNA chip which contains an 
interconnected set of microchannel used for separation of nucleic acid fragments 
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based on size. Samples with an RNA integrity number (RIN) of >8 were used for 
glycogene expression analysis.  
 
2.10: Complementary DNA (cDNA) Synthesis. 
 
RNA samples were reverse transcribed in order to synthesise complementary 
DNA (cDNA) for quantification of gene expression. The High-Capacity RNA-to-
cDNA™ Kit (Applied Biosystems, 4387406) was used according to the 
manufacturer’s instructions. The reaction contained 1X RT buffer mix with 1µL of 
RT enzyme and 2 µg of total RNA. RNase-free water was added to the reaction 
to 20 µL. Negative control cDNA reactions lacked reverse transcriptase enzyme. 
Reactions were incubated at 37°C for 60 minutes followed by 5 minutes at 95°C 
in a thermal cycler (2720 Thermal Cycler Applied Biosystems, UK) and cDNA 
was stored at -20°C. 
 
2.11: Oligonucleotide design. 
 
Oligonucleotides were either designed in accordance to the criteria of Thornton 
and Basu (2011), obtained from the Harvard University PrimerBank 
(https://pga.mgh.harvard.edu/primerbank/index.html) or taken from published 
sources.  All forward and reverse sequences were subject to BLAST analysis to 
assess self-complementarity and specificity 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). All oligonucleotides were 
purchased from MWG Eurofins (Ebersberg, Germany), diluted to a stock 
concentration of 100μM in nuclease free water (Ambion) and stored at -20°C. 
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Table 2.4: Oligonucleotides used in this study. 
Target 
Gene 
Accession 
number 
Sequence 5’-3’. Forward (F) and 
reverse (R).  
Reference/ 
Harvard 
Database ID 
-Actin NM_001101.3 
F:GGGAAATCGTGCGTGACATT 
R:CCACAGGACTCCATGCCC 
 
β2M NM_004048.2 
F: GAGGCTATCCAGCGTACTCCA 
R: CGGCAGGCATACTCATCTTTT 
37704380c1 
B3GNT2 NM_006577 
F: TCCAAAAGCAGTAGCCAAGAAA 
R: CGGTTCCAGTATGCCTCGG 
92091578c1 
B4GALT1 NM_001497 
F: GGCGTCACCCTCGTTTACTAC 
R: GGGCCAGAATCCACGACTG 
193211604c1 
B4GALT2 NM_001005417 
F: CTGCTTAACGTGGGCTTCCTA 
R: GTCCACATCGCTGAAGATGAA 
339276011c3 
B4GALT3 NM_001199874 
F: CGAGATCAGGGACCGACATTT 
R: GATCGTTCTGGACAGTAGGGC 
315467843c1 
CA9 NM_001216 
F: AGGGTGTCATCTGGACTGTG 
R:TGTGTGGCTCGGAAGTTCAG 
Martín-
Aragón 
Baudel et al., 
(2017) 
EPO NG_021471.2 
F:GAATATCACTGTCCCAGACACC 
R:CCCTGCCAGACTTCTACGG 
Martín-
Aragón 
Baudel et al., 
(2017) 
GALNT3 NM_004482 
F: CAGCAGAATTGAAGCCTGTCC 
R: CTTCCCCACGTTCCTTTTCCT 
153266877c1 
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Table 2.4 continued: Oligonucleotides used in this study. 
GALNT6 NM_007210.3 
F:ACTCTGTTCTCCATAAACCAGTC 
R: CTGGCAAAGGCATTGAAACA 
 
GALNT7 NM_017423.2 
F: TCACCTCACACTACCCTTTGC 
R: CTGATTCCCTCCCATCCTGT 
Munkley et 
al., (2016) 
GALNT12 NM_024642 
F: GAGGGGCGATGTTCTGACC 
R: TGCCGACTCCTCTTCATGGA 
325651866c3 
GALNT14 NM_001329097.1 
F: TAGCATCATCATCACCTTCCAC 
R: TTACAGTCATCAGGGTCATTGC 
Huanna et 
al., (2015) 
GALNTL5 NM_145292.3 
F: GAAGCTTGGGCATCGAAA 
R: GCGGGCTGGGTAATGTT 
Takasaki et 
al., (2014) 
HIF-1 NM_001243084 
F:GTACCCTAACTAGCCGAGGAAGAA 
R:GTGAATGTGGCCTGTGCAGT 
Martín-
Aragón 
Baudel et al., 
(2017) 
HIF-2 NM_001430 
F:ACCTGGAAGGTCTTGCACTGC 
R:TCACACATGATGATGAGGCAGG 
Martín-
Aragón 
Baudel et al., 
(2017) 
RPLP0 NM_001002.3 
F: CCTCATATCCGGGGGAATGTG 
R: GCAGCAGCTGGCACCTTATTG 
Untersmayr 
et al., (2010) 
Vimentin NM_003380.4 
F: AGATTCAGGAACAGCATGTCC 
R: AGCCTCAGAGAGGTCAGC 
Martín-
Aragón 
Baudel et al., 
(2017) 
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2.12: End-point PCR and gel electrophoresis.  
End-point PCR amplification was performed in a 10 µL reaction containing 
approximately 100 ng of genomic template DNA, 10 µM of each primer (forward 
and reverse), 2 x Mangomix (Bioline) and 2 µL nuclease free H2O. Control 
reactions included a negative RT control and a nuclease free H2O primer only 
control. Cycling conditions included a 5-minute denaturing at 94°C, 40 cycles of 
amplification and annealing entailing 15 seconds at 94°C, 15 seconds at 50°C 
and 30 seconds at 72°C. All reactions were completed at 4°C. PCR products 
were analysed by gel electrophoresis.  
Gel electrophoresis was performed on 1% agarose gels in 50 x Tris-acetate-
EDTA (TAE buffer). Gels were supplemented with 0.005% Safeview for RNA 
visualisation. Samples were loaded on the gels and electrophoresed at 120V until 
the dye front travelled approximately ¾ of the way down the gel. Electrophoresed 
gels were visualised on a UV-trans-illuminator. 
 
2.13: RT2 Human Glycosylation Array.  
 
To determine the glycogene expression profile of Tumours 11004 and 10046 and 
respective tissue matched samples, a commercially available glycosylation array 
was used (RT2 Human Glycosylation Array, PAHS-046Z, Qiagen). Tumour 10076 
and tissue matched samples were not used in this analysis. Equal concentrations 
of RNA (250 ng) were reverse transcribed to cDNA using the RT2 First Strand Kit. 
The genomic DNA elimination mix was prepared by adding 250 ng of RNA to 2 
μL GE buffer. The genomic DNA elimination mix was incubated for 5 minutes at 
42°C, then immediately placed on ice. Reverse transcription mix was prepared 
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by combining Buffer BC3, control P2, RE3 Reverse Transcriptase Mix and 
RNase-free water to total 10 µL for each reaction. The Reverse Transcription Mix 
was mixed by pipetting before 10 µL genomic DNA elimination mix was added. 
Reactions were incubated at 42°C for 15 minutes and the reaction stopped by 
incubating at 95°C for 5 minutes.  RNase-free water (91 µL) (Ambion) was added 
to each reaction. Quantitative-PCR (qPCR) master-mix was prepared by mixing 
1X RT2 SYBR Green Master-mix, cDNA synthesis reaction and RNase-free 
water to a reaction total of 2.7 mL and 25µL of this mixture was pipetted into each 
well of the RT2 PCR array. Gene expression levels were quantified by Q-PCR 
(StepOne™ Real Time PCR system (ThermoFisher Scientific, UK): 1 cycle of 
95°C for 10 minutes, 40 cycles of 15s seconds at 95°C and 1 minute at 60°C. 
PCR array data analysis software (Sabiosciences RT2 PCR profiler array v3.5) 
was used to normalise the data and calculate the fold change in gene expression. 
The CT thresholds were adjusted based on positive PCR controls (PPC), which 
monitor for PCR inhibitors, so that they fell between the advised 20 +/- (2) stated 
in the manufacturer’s instructions. Housekeeper genes Ribosomal Protein Lateral 
Stalk Subunit P0 (RPLP0) and beta-2-microglobulin (β2M) were used to 
normalise the gene expression data of Tumours 11004 and 10046, respectively. 
Selection of housekeeper genes were based on stable CT values across both the 
tumour and matched tissue samples as indicated by Sabiosciences RT2 PCR 
profiler array v3.5 software.   
 
2.14: qRT-PCR. 
 
Independent qRT-PCR reactions (20 μL) contained 1 μL of forward and reverse 
oligonucleotides at a final concentration of 150 nM, 10 μL PrimerDesign Precision 
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qRT-PCR Mastermix and either 11.7 ng or 12.5 ng of template cDNA from tumour 
samples or MDA-MB-468 TNBC cells, respectively, in nuclease-free H2O 
(Ambion). Controls included RNA from a reaction without reverse transcriptase 
(negative control) and cDNA replaced with nuclease-free water (template 
negative). Reactions were performed in triplicate using a StepOne™ Real Time 
PCR system (ThermoFisher Scientific). Instrument settings were as follows: 10 
minutes at 95°C plus 40 cycles at 95°C for 15 seconds followed by 1 minute at 
60°C. Melt curve analysis, which measures fluorescence at increasing 
temperature intervals (60°C to 95°C at 0.3°C intervals) was used for the 
identification of a single amplified product. Data was normalised to the geometric 
mean of β-actin, RPLP0 and β2M housekeeper genes and fold change in gene 
expression was calculated using the delta-delta CT method (Livak and 
Schmittgen, 2001). For siRNA analysis, gene expression was normalised to β2M.  
 
2.15: Protein Extraction and quantification by Bradford analysis. 
 
Cell pellets were lysed by resuspending the pellet in 3x the pellet volume with 
NP40 lysis buffer (50mM Tris, 150mM NaCl, 5mM EDTA, 1% NP40,) 
supplemented with 1x protease inhibitor (Thermofisher Scientific, UK). Cells were 
incubated on ice for 30 minutes and centrifuged at 16000xg (5415R, Eppendorf) 
for 5 minutes at 4°C. Protein concentration from the clarified supernatant was 
determined by Bradford analysis where a stock of 2 mg/ mL bovine serum 
albumin (BSA) prepared in dH2O was used to generate a standard curve of known 
protein concentrations (1.5 – 0.125 mg/ mL). Protein samples were diluted 1:5 in 
dH2O and 1 μL dilution was mixed with 200 μL Bradford reagent (100mg 
Coomassie blue G-250, 95% ethanol, 85% (w/v) phosphoric acid) in a 96 well 
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plate. A blank control was generated by mixing 1 μL of dH2O with 200 μL Bradford 
reagent. Absorbance at 550nm was determined after 5 minutes of incubation at 
room temperature by plate reader (ELISA reader LT-5000MS, LabTech 
International) using Manta Lite software (LabTach International). A standard 
curve was generated from the known standards and the unknown protein 
concentrations were determined by their absorbance.  Protein samples were 
diluted in 4X Loading Sample Buffer (LSB) (20% glycerol, 200mM Tris pH 6.8, 
4% SDS, 10mM EDTA, and bromophenol blue) to give a final concentration of 1 
mg/ mL and boiled at 100 °C for 2 minutes. Samples were then stored at -20°C 
before use. 
 
2.16.1: Sodium Dodecyl Sulphate – Polyacrylamide Gel Electrophoresis 
(SDS-PAGE). 
 
Proteins were resolved via SDS-PAGE based on methods by Laemmli, (1970). 
Resolving acrylamide gels were composed of 8-12% (w/v) acrylamide (30% w/v 
stock acrylamide); resolving Tris solution (0.375 mM Tris-HCl, 0.1 (w/v) SDS 
adjusted to pH 8.8 and 10% (w/v) ammonium persulphate (AmPs). To polymerise 
the mixture 0.1% N,N,N′,N′-Tetramethylethylenediamine (TEMED) (Sigma-
Aldrich) was added. After polymerisation the stacking gel was prepared and (5% 
(w/v) polyacrylamide, 1M Tris-HCL (pH = 6.8), 10% SDS, 10% AmPs) and 0.1% 
TEMED was added to promote polymerisation.  
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2.16.2: Resolving SDS-PAGE gels 
 
Gels were removed from their casting chambers and placed into an 
electrophoresis tank (BioRad) and submerged in 1x running buffer (25 mM Tris-
HCL, 192 mM Glycine, 35 mM SDS). Typically, for HIF-1 and HIF-2 protein 
expression 30 μg of cell lysate was resolved on an 8% SDS-polyacrylamide gel, 
for β-actin expression 10 μg was resolved on an 12% gel. A pre-stained broad 
range protein marker (PageRuler™ Prestained Protein Ladder, 10 to 180 kDa, 
ThermoFisher Scientific) was used to determine the size of the proteins of 
interest. The gels were electrophoresed at 185V for approximately 60 minutes or 
until the blue loading buffer dye front reached the bottom of the SDS gel.  
 
2.16.3: Immunoblotting 
 
Following the separation of proteins via SDS-PAGE they were transferred onto a 
nitrocellulose membrane following the methods of Towbin et al., (1979). The 
nitrocellulose membrane (0.2 μm, Optiran BA-S 83) was sandwiched between 
paper (2mm, Whatman International Ltd., UK) and a transfer sponge soaked in 1 
x transfer buffer (0.25M Tris pH 8.5, 0.2 M Glycine, 20% Methanol). The sandwich 
was assembled under 1x transfer buffer, compressed with a plastic tube to 
remove air bubbles. The sandwiches were inserted into the apparatus and 
submerged with 1x transfer buffer. An ice pack was added to the chamber then 
samples were electrophoresed 100V for 1 hour or at 30mA for 16 hours at 4°C. 
The nitrocellulose membrane was stained with Ponceau S solution (0.1% 
Ponceau S, 5% acetic acid) to ensure equal transfer of proteins, washed three 
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times in PBS with 1% tween (PBS-T) and blocked with 5% (w/v) non-fat milk 
(Marvel) or 5% BSA in PBS-T for one hour at room temperature with shaking. 
 
2.16.4: Immunostaining  
 
Primary antibodies were prepared at a dilution of 1:1000-1:750. The nitrocellulose 
membrane was incubated with specific primary monoclonal antibody (Table 2.5) 
in 5 % non-fat milk in 1x PBS-T overnight at 4°C. The membrane was washed 
three times in PBS-T before probing with the secondary antibody for 45 minutes 
(Table 2.5.1) at a dilution of 1:10000 in 5 % non-fat milk containing 0.01 % SDS. 
The membrane was then washed three times in PBS-T. Membranes were 
analysed by LI-COR Odyssey imaging system (Odyssey-3074, LI-COR, 
Cambridge, UK) and Odyssey Image Studio v2.0 software (ThermoFisher 
Scientific, UK).  
 
Table 2.5: Primary antibodies used in this study. 
Antigen Antibody Species Company Cat.No Dilution 
-actin actin C-11 Goat Santa Cruz sc-1615 1:1000 
HIF-1 
anti- 
HIF-1α 
Human 
BD 
Biosciences 
610958 1:1000 
HIF-2 
anti-HIF-
2α 
Goat 
R&D 
Systems 
AF2886 1:750 
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Table 2.5.1: Secondary antibodies used in this study. 
Species Conjugate Company Cat.No Dilution 
Anti-goat 680LT LI-COR 925-68024 1:10000 
Anti-mouse 800CW LI-COR 926-32210 1:10000 
 
2.17: Statistical Analysis  
 
All statistical analysis was performed using GraphPad Prism v.7 (GraphPad 
Software).  Results are shown as the mean ± standard error of the mean (SEM), 
where n=3. To determine significance of fold change in gene expression data 
between tumour samples and cell replicates an unpaired Students t-test and 
Wilcoxon signed-rank test was used. For Lectin binding analysis two-way ANOVA 
with Šidàk’s multiple comparisons was used. For siRNA analysis two-way 
ANOVA was used with Tukeys multiple comparison test was used where *p ≤ 
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. 
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Chapter 3: Determining the glycogene expression profile of triple 
negative breast cancer. 
 
3.1: Introduction 
 
3.1.1: Altered glycans in breast cancer. 
 
Aberrant protein glycosylation is a hallmark of many human cancers including 
breast cancer (Hanahan and Weinberg, 2011). Glycans, which can be detected 
by lectins, are formed by N- or O- glycosylation and their function spans from 
relatively subtle to crucial for life, development, growth and functioning (Varki and 
Lowe, 2009). Under neoplasia, there are changes promoting specific alterations 
to N- and O-linked core structures, glycogene expression and the degree of core 
glycan branching (Song et al., 2001; Stowell, Ju and Cummings, 2015); thus 
potentially altering glycan structure and function.  
Aberrant O-linked glycosylation has been observed in over 90% of breast cancer, 
(Burchell et al., 2018) most prevalently through the loss of core-2 glycans and 
expression of Tn antigen (Au et al., 2014) (Figure 3.1). Sialylation of the Tn 
antigen involves the addition of a terminal sialic acid which averts further 
elongation of the structure resulting in premature truncation and potentially loss 
of glycan function (Figure 3.1) (Brockhausen, Schachter and Stanley, 2009). 
Core 2 structures however, can be cleaved to more simple sugars which results 
in breast cancers overexpressing Tn antigen (Core 1) (Springer, 1984). 
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Figure 3.1: Antigens and core structures from the initiation of mucin-type 
O-linked glycosylation. (A) Incomplete glycosylation results in the carcinoma 
hallmark expression of T, Tn, ST and STn- antigens (Varki et al., 2015). Core 1 
O-GalNAc is found in many glycoproteins and it is termed the T antigen. The first 
sugar (GalNAc) added to this molecule creates the Tn antigen. Both the T and 
Tn antigen can be further modified by sialic acid to form sialylated-T or Tn 
antigens (Beatson et al., 2015; Brockhausen et al., 2009). (B) The formation of 
linear and branched mucin-type O-glycans showing the steps leading to the 
synthesis of core 1-4 di- and tri-saccharides (Corfield and Berry, 2015).  
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3.1.2: Aberrant glycogene expression in BrCa.   
 
Glycogene expression in breast cancer cells compared to adjacent tissues have 
demonstrated significant differences in expression, with increased levels of 
sialyltransferases including ST8SIA4 (Ma et al., 2016). The highly metastatic 
TNBC cell line MDA-MB-231 likewise displays increased expression of ST8SIA4, 
which may promote aggressive tumour growth (Ma et al., 2016).  BrCa growth 
has furthermore been attributed to overexpression of C1GALT1 through altered 
O-glycan structures on MUC1 (Chou et al., 2015); a transmembrane protein that 
participates in intracellular signalling transduction pathways (Nath and 
Mukherjee, 2014). Breast cancer cell metastasis can be facilitated by altered 
glycosylation gene expression. For example, ST6GalNAc5 enables BrCa 
metastasis to the brain through cancer cell adherence to the brain endothelium 
and blood-brain barrier permeability (Bos et al., 2009).  
 
3.1.3: Hypoxia and altered glycosylation in breast cancer.  
 
Tumour hypoxia has been linked to aggressive phenotypes, chemoresistance 
and treatment failures of breast cancer (Generali et al., 2006; Bos et al., 2009). 
Hypoxia inducible factor 1- (HIF-1) regulates the transcription of various genes 
controlling tumour responses to hypoxia, including angiogenesis (López-Barneo, 
Pardal and Ortega-Sáenz, 2001). One of the many alterations in cancer is altered 
energy metabolism (Hanahan and Weinberg, 2011). HIF activates genes 
involved in glucose transport, such as GLUT1 and GLUT3, which causes 
increased glucose consumption to meet the high metabolic demand for 
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nucleotide sugar biosynthesis (Cheng et al., 2006). GLUT1 and GLUT3 also 
promote cell replication (Goda, Dozier and Johnson, 2003). Due to the dramatic 
shift in cell metabolism caused by hypoxia, the expression of glucose transporters 
and glycolytic enzymes; glucose metabolic patterns may be altered (Shirato et 
al., 2011). This suggests that hypoxia has an important role in the modulation of 
nucleotide sugar biosynthetic pathways (Taniguchi, 2007). Furthermore, 
glycosylation is kinetically regulated by the dynamic portfolio of glycosylation 
genes, nucleotide sugars and nucleotide transporters (Shirato et al., 2011). A 
deficiency or excess in the expression of glycosylation genes has been linked to 
aberrant glycosylation, which may contribute to the development and progression 
of breast cancer (Taniguchi, 2007). Nucleotide sugar availability can also 
modulate glycosylation due to their importance in glycan synthesis (Taniguchi, 
2007). The absence or surplus of nucleotide sugars may result in a number of 
glycan alterations including excessive elongation or premature truncation 
(Potapenko et al., 2010) Collectively, these modifications may then lead to an 
aggressive breast cancer phenotype and facilitate metastasis (Asada et al., 1997; 
Kölbl, Andergassen and Jeschke, 2015).  
By investigating the altered expression of glycosyltransferase genes, a better 
understanding of the cellular glycome in malignancy will be gathered; leading to 
identification of potential biomarkers of disease and better treatment options. In 
this investigation, TNBC samples and tissues matched controls were used to 
assess the glycosylation profile of TNBC. By comparing gene expression of 
tumour tissue and the patient matched samples, interpatient variability was 
eliminated resulting in highly proficient data. Glycosylation gene profiling was 
validated in hypoxic MDA-MB-468 TNBC cells, which effectively replicated the 
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tumour microenvironment in vitro. MDA-MB-468 cells are a well-established 
model of TNBC have been used extensively in BrCa research (Reilly, 2007).   
 
3.2: Aims 
 
Aim 1: To profile the change in expression of key glycogenes in human TNBC 
tumour samples and validate these changes hypoxic MDA-MB-468 cells as an in 
vitro model of TNBC. 
 
Aim 2: To determine the lectin binding profile of hypoxic MDA-MB-468 cells. 
 
3.3: Research Questions 
 
RQ1: Does the glycosylation gene expression profile in TNBC differ to tissue 
matched control samples?  
 
RQ2: Do hypoxic MDA-MB-468 cells share similarities in the glycosylation gene 
expression profile of TNBC tumour samples and have altered expression of key 
glycogenes?  
 
RQ3: Is the glycan profile of MDA-MB-468 cells altered in response to acute 
hypoxia?  
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3.4: Results 
 
3.4.1: Profiling the differences in glycogene expression between TNBC 
tumours and their tissue matched controls. 
 
To identify glycosylation genes with altered expression in TNBC, a commercially 
available glycosylation qRT-PCR array was employed to assess the expression 
profile in TNBC tumours (11004 and 10046) and their patient-matched non-
cancerous breast tissue controls. The RT2 Human Glycosylation Array profiled 
eighty-four genes encoding glycosylating enzymes. The array included 
housekeeper genes (-actin, β2M, GAPDH, HPRT1 and RPLP0), as well as 
controls for reverse transcription, reaction success and human genomic DNA 
contamination. CT values were compared between the tumour and its respective 
tissue-matched control. Genes with greater than 2-fold change in expression 
were taken to have altered expression.  
Gene expression for each sample tumour was expressed as a heat map (Figure 
3.2). In tumour 11004, sixty glycosylation enzymes were upregulated, including 
those from the 5 major glycosylation families: glycan extension, O-glycan 
initiating, N-glycan branching, sialidases and sialyltransferases. Eleven 
glycogenes were downregulated (Figure 3.2), including: A4GNT, GALNT9, 
GALNT12, GALNT16, GALNTL5, MGAT4C, NEU2, NEU4, ST6GALNAC1, 
ST8SIA3 and ST8SIA6 whilst thirteen glycosylation genes remained unchanged 
between tumour 11004 and its tissue matched control. In tumour 10046, forty 
genes were upregulated, three glycogenes were downregulated including 
GALNT13, GCNT1 and MAN2A2 and forty-one glycogenes remained unchanged 
compared to the tissue matched control (Figure 3.2).  
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Altered gene expression was observed in tumours 11004 and 10046 compared 
to their respective tissue matched controls – indicating that TNBC glycogene 
expression does indeed differ to tissue matched control samples. However, inter-
individual variation was observed with each woman presenting with a different 
glycosylation profile - although upregulated glycogene expression in TNBC was 
the general trend.  
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Figure 3.2: Profiling the change in glycosylation gene expression in TNBC. 
Heat map visualisation of the fold changes in gene expression between tumour 
11004 (A) and tumour 10046 (B) and their respective tissue matched controls. 
Each pixel represents a gene and its colour indicates the magnitude of change in 
gene expression compared to its respective matched control; with green 
indicating upregulation, red indicating downregulation and grey showing no 
change: Scale bars show the magnitude of fold change in gene expression. Rows 
A-G and 01-12 represent the 84 key glycosylation genes profiled in this array. 
Samples were assessed by qRT-PCR and analysed with Sabiosciences data 
analysis software v2.3  
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3.4.2: Glycan-extension genes. 
 
The glycosyltransferase family of genes encode extension enzymes which are 
responsible for the transfer of mucin-type O-glycans to glycoproteins as they 
cross the Golgi apparatus (Freeze & Ng, 2011). In tumour 11004, seventeen 
glycan-extending genes were upregulated including: B3GLCT, B3GNT2-4, 
B3GNT8, B4GALT1-3, B4GALT5, C1GALT1, C1GALT1C1, GCNT1, OGT, 
POMGNT1, POMT1-2 and UGGT. A4GNT was the only downregulated 
extension gene in 11004, whilst GCNT3, GCNT4 and UGGT2 expression 
remained unchanged (Figure 3.3). In comparison, 8 glycan-extension genes were 
upregulated in 10046 including: B3GLCT, B3GNT2, B4GALT1-3, C1GALT1C1, 
OGT and POMT2 (Figure 3.4). Expression of A4GNT, B3GNT3, B3GNT4, 
B3GNT8, B4GALT5, C1GALT1, GCNT3, GCNT4, POMGNT1, POMT1, and 
UGGT2 remained unchanged between tumour 10046 and its matched control 
(Figure 3.4).  
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Figure 3.3: Analysis of the glycogene expression profile in TNBC tumour 
11004.  
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Figure 3.3 Continued: Analysis of the glycogene expression profile in TNBC 
tumour 11004. Expression of key glycosylation enzymes were profiled by qRT-
PCR. qRT-PCR values were normalised to housekeeper gene RPLP0 expression 
and analysed with Sabiosciences software v2.3 and Graphpad Prism 7.  
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3.4.3: O-glycan initiating genes. 
 
O-Glycan initiating genes (GALNTs) are involved in the addition of N-
acetylgalactosamine residues from the nucleotide sugar donor UDP-GalnNac to 
a serine or threonine residues. (Ju et al., 2014).   Ten O-glycan initiating genes 
were upregulated in tumour 11004 including: GALNT2, 3, 4, 6, 7, 8, 10, 11, 13 
and 14. Four O-glycan initiating enzymes were downregulated including: 
GALNT9, 12, 16 and L5, whilst GALNT1 and GALNTL6 remained unchanged 
(Figure 3.3). 
Nine O-glycan initiating genes were upregulated in tumour 10046 including: 
GALNT1, 3, 4, 6, 7, 11, 12, 14 and L5. The expression of six O-glycan initiating 
genes remained unchanged including: GALNT2, 8, 9, 10, 16 and L6 whilst 
GALNT13 was downregulated (Figure 3.4). This data may indicate that altered 
O-glycan initiating gene expression is common in TNBC and these alterations 
may impact the subsequent glycosylation reactions occurring after initiation.  
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Figure 3.4: Analysis of the glycogene expression profile in TNBC tumour 
10046.  
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Figure 3.4 continued: Analysis of the glycogene expression profile in TNBC 
tumour 10046. Expression of key glycosylation enzymes were profiled by qRT-
PCR. qRT-PCR values were normalised to housekeeper gene β2M expression 
and analysed with Sabiosciences software v2.3 and Graphpad Prism 7.  
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3.4.4: N-glycan branching genes. 
 
N-Glycans are subject to a number of branching modifications including the 
addition and removal of mannose, D-glucose, N-acetylglucosamine, fucose and 
sialic acids (Legler et al., 2018). Twelve N-glycan branching enzymes were 
upregulated in tumour 11004 including: MAN1A2, MAN1B1, MAN2A1-2, 
MAN2B1, MANBA, MGAT1-3, MGAT4A, MGAT4B and MGAT5. The expression 
of MAN1A1, MAN1C1 and MGAT5B remained unchanged whilst MGAT4C was 
downregulated (Figure 3.3). 
By contrast, N-glycan branching genes: MAN1C1, MAN2B1, MGAT4A, MGAT4B, 
MGAT4C and MGAT5 were upregulated in tumour 10046 whilst MAN2A2 was 
downregulated. MAN1A1, MAN1A2, MAN1B1, MAN2A1, MANBA, MGAT1-3 and 
MGAT5B gene expression remained unchanged (Figure 3.4). This data suggests 
that N-glycan branching and cleaving may be altered leading to aberrant 
glycosylation’s on the surface of TNBC cells.  
 
3.4.5: Sialidase and Sialyltransferase genes 
 
The sialidases/sialyltransferase enzymes are responsible for the addition or 
removal of N-acetylneuraminic acid residues on glycans. NEU1, NEU3, 
ST3GAL1, ST3GALT2, ST6GAL1, ST8SIA2 and ST8SIA4 were dramatically 
upregulated in tumour 11004 whilst: NEU2, NEU4, ST6GALNAC1, ST8SIA3 and 
ST8SIA6 expression was downregulated (Figure 3.3). 
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Sialyltransferase enzymes: ST3GAL1, ST6GAL1, ST6GALNAC1 and ST8SIA2 
were upregulated in tumour 10046 whilst NEU2, 3, 4, ST3GAL2, ST8SIA3, 
ST8SIA4 and ST9SIA6 expression remained unchanged (Figure 3.4). Due to the 
upregultion of both sialic acid transferases and cleaving enzymes, it is highly 
likely that the sialic acid containing residues are altered on the surface of TNBC 
cells, leading to altered cell function.  
 
3.4.6 Endoplasmic reticulum, decoration and trimming genes. 
 
In addition to the main families of glycogenes several other important glycogenes 
were profiled including endoplasmic reticulum-degradation (ERAD), decoration 
(fucosyltransferase) and trimming (fucosidase, hexosaminodase) genes. 
EDEM1, EDEM3, FUT8, GABAB, GLB1, MOGS, PRKCSH, HEXA and HEXB 
were upregulated in both tumours 11004 and 10046 whilst, NAGPA, EDEM2, 
FUT11, FUCA2, POFUT1 and POFUT2 were only upregulated in tumour 11004. 
FUCA1 and GNPTAB were upregulated in tumour 10046 but expression 
remained unchanged in tumour 11004 (Figure 3.5). This suggests that the altered 
glycosylation profile of TNBC may extend to all aspects of glycosylation including 
trimming, initiating and decoration.  
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Figure 3.5: ERAD, decoration and trimming genes. Using a RT2 profiler array, 
expression of key glycosylation enzymes were profiled by qRT-PCR. The fold 
change in gene expression is shown in tumours 11004 and 10046 for each gene. 
Unchanged gene expression is not shown. Data was normalised to housekeeper 
genes β2M and RPLP0 for tumour 10046 and 11004 respectively and analysed 
with Sabiosciences software v2.3 and Graphpad Prism 7. 
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3.4.7: Pilot analysis of glycogene expression suggests altered expression 
in TNBC. 
 
Extensive qRT-PCR profiling of two TNBC tumours shows there are marked 
changes in glycogene expression in TNBC compared to matched tissue control 
samples. Furthermore, the glycogene expression alterations in TNBC was not 
limited to one family of enzymes, but to several groups including glycan extension 
enzymes, O-glycan initiating genes, N-glycan branching genes, sialidases and 
sialyltransferase genes. 
As a result of the widespread upregulation of glycogenes in TNBC samples, it 
would be expected that glycan profiles would be altered on TNBC cells and 
therefore, glycan function may be changed. From the two TNBC tumours 
analysed, differences in glycogene expression were found which could be 
representative of multiple aberrant glycosylation’s present in TNBC.  
 
3.4.8: QRT-PCR validation of selected glycosylation gene expression in 
TNBC tumour samples.  
 
The genes showing the most substantial changes in gene expression between 
tumours 11004 and 10046 (figure 3.3-3.5) were validated by independent qRT-
PCR. Originally, tumour 10076 was not used in array profiling due to available 
array resources however, it could be included in QRT-PCR analysis to provide a 
more well-rounded understanding into changes in glycosylation gene expression 
in TNBC. RNA from the tumours and tissue matched controls was reverse 
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transcribed to cDNA and successful reverse transcription was assessed by end-
point PCR amplifying the housekeeping gene -actin as a positive control (Figure 
3.6). The resulting gel electrophoresis showed clear bands present at 202bp in 
the +RT lanes of 11004, 10046 and 10076 in both the matched tissue control (C) 
and tumour (T) samples. The cDNA was therefore acceptable to use in qRT-PCR 
analysis. Gene expression was normalised to the geometric mean of 
housekeeper gene expression, -actin, β2M and RPLP0, as they were stable 
references for normalisation.  
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Figure 3.6:  Verifying cDNA synthesis from tumour RNA. End point PCR was 
used to analyse cDNA synthesis reactions from RNA of TNBC tumours 11004, 
10046 and 10076 and their respective tissue matched controls. Gel 
electrophoresis was used to resolve cDNA in 1x TAE buffer.  Reactions contained 
DNA prepared with (+) or without (-) reverse transcriptase or with cDNA replaced 
with dH2O (NTC). (L) Ladder. (C) Control. (T) Tumour. RT: Reverse transcriptase. 
 
3.4.9: Validating altered expression the O-glycan initiating genes in TNBC.  
 
Initially, O-glycan initiating genes (GALNT3, GALNT6, GALNT7, GALNT12, 
GALNT14 and GALNTL5) were chosen for validation due to their intense 
upregulation in both TNBC samples and expression was assessed in tumours; 
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11004, 10046 and 10076 and their respective tissue matched controls (Figure 
3.7). 
In keeping with the array data GALNT3, 6, and 7 expression was upregulated in 
tumours 11004 and 10046 compared to control tissue. GALNT12 and L5 were 
upregulated in tumours 11004 and 10046 in the qRT-PCR validation, however 
these genes were only upregulated in tumour 10046, in the array profiling. 
GALNT3 was significantly upregulated (p>0.05). GALNT14 was upregulated in 
tumours 11004 and 10076 yet was downregulated in tumour 10046. GALNT6, 7, 
12, and L5 expression was downregulated in tumour 10076 (Figure 3.7).  
This data proposes that O-glycan initiating gene expression is altered in TNBC. 
This would suggest that there are alterations in O-glycan structures in TNBC 
which may result in prematurely truncated or highly branched glycan structures.  
  
75 
 
 
Figure 3.7: Comparing the expression of selected O-glycan initiating enzymes in TNBC.  
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Figure 3.7 continued: Comparing the expression of selected O-glycan initiating enzymes in TNBC: qRT-PCR values were 
normalised to the geometric mean of housekeeper genes (-actin, β2M and RPLP0) and the fold change in gene expression 
was calculated by the [delta][delta]CT method (Livak and Schmittgen, 2001). Shown is the fold change in gene expression from 
two technical replicates. Statistical analysis was performed on [delta]CT values with the Student’s t-test *p>0.05. The dotted line 
represents basal (i.e unperturbed) gene expression 
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3.4.10: Validating the glycosyltransferases, sialidases and sialyltransferase 
in TNBC.  
 
The expression of a further five genes (B3GNT2, B4GALT2, B4GALT3, NEU1 
and NEU3) were chosen for validation tumours 11004, 10046 and 10076 due to 
their intense upregulation (Figure 3.8). B3GTN2, B4GALT2, B4GALT3, NEU1 
and NEU3 expression was upregulated in tumours 11004 and 10046.  In tumour 
10076, B4GALT2, B4GALT3 and NEU1 expression was downregulated whilst 
B3GNT2 and NEU3 were upregulated (Figure 3.8).  
This data suggests that glycan-extension enzymes and sialidase enzymes are 
altered in TNBC which may result in aberrant cell glycosylation with abnormal 
glycan structures, facilitating aggressive tumour growth.
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Figure 3.8: Analysis of glycosyltransferases and sialidases in TNBC.  
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Figure 3.8 continued: Analysis of glycosyltransferases and sialidases in TNBC (A-C) The relative mRNA expression of 
glycosyltransferase enzymes B3GNT2, B4GALT2 and B4GALT3 and sialidase enzymes NEU1 and NEU3 (D&E) were analysed 
by qRT-PCR in TNBC tumour samples (11004, 10046 and 10076) compared to their respective tissue matched controls. Shown 
is the fold change in gene expression from two technical replicates. qRT-PCR values were normalised to the geometric mean 
of housekeeper genes (-actin, β2M and RPLP0). Fold change in gene expression was calculated by the [delta][delta]CT method 
(Livak and Schmittgen, 2001). The dotted line represents basal (i.e unperturbed) gene expression
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3.4.11: Correlating glycogene expression with hypoxia in TNBC. 
 
TNBC is an inherently hypoxic tumour (Bernardi and Gianni, 2014). Therefore, 
expression of HIF-1 and HIF-2 was analysed in tumour samples 11004, 10046 
and 10076 by qRT-PCR to assess the degree of hypoxia (Figure 3.9). 
Interestingly, HIF-1 was upregulated in all three TNBC samples whilst HIF-2 
expression was downregulated (Figure 3.9). Expression of the HIF downstream 
target gene CA9 (Semenza, 2000) was used to assess HIF-1 activation. CA9 
expression in all 3 TNBC samples was dramatically upregulated and correlated 
with HIF-1 expression in each sample. HIF-2 downstream targets were not 
analysed due to insufficient quantities of RNA. This data confirms TNBC tumours 
11004, 10046 and 10076 were highly hypoxic and activation of HIF signalling was 
evident (Figure 3.9).  
The degree of HIF-1 and HIF-2 expression was found to correlate with the 
trend in expression of glycogenes (Figures 3.7 - 3.9). Expression of GALNT3, 
GALNT6, GANT7, GALNT12, B3GNT2, B4GALT3, NEU1 and NEU3 was 
greatest in tumour 11004, was moderately expressed in tumour 10046 and was 
least expressed in tumour 10076, following the trend of HIF-1 expression in 
these samples (Figures 3.7 – 3.9).  This trend suggests a possible correlation 
between HIF-1 induction and glycogene expression.  
By contrast, expression of GALNTL5 correlated with HIF-2 expression in 
tumours 11004, 10046 and 10076 (Figures 3.7 and 3.9), suggesting expression 
of certain glycogenes such as GALNTL5 may correlate with or be regulated by 
HIF-2 signalling.  
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Figure 3.9: Expression of Hypoxia Inducible Factors and downstream target 
in TNBC.  The fold change in gene expression of HIF-1, HIF-2 and CA9, was 
analysed by qRT-PCR in TNBC tumours 11004, 10046 and 10076 compared to 
their respective tissue matched controls. Shown is the fold change in gene 
expression from two technical replicates. qRT-PCR values were normalised to 
the geometric mean of housekeeper genes β-actin, β2M and RPLP0. The dotted 
line represents basal (i.e unperturbed) gene expression.  
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3.4.12: Using hypoxic MDA-MB-468 cells as a model of TNBC. 
 
Hypoxic MDA-MB-468 cells were used as an in vitro model of TNBC. Cells were 
exposed to acute hypoxia (1% O2) for 22 hours and protein expression of HIF-1 
and HIF-2 was assessed by immunoblotting (Figure 3.10). Clear bands were 
observed in hypoxic cells at approximately 116kDa for HIF-1 and 118kDa for 
HIF-2 indicating that these conditions successfully induced hypoxia and HIF 
stabilisation (Figure 3.10).  
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Figure 3.10: Analysis of HIF-1 and HIF-2 protein expression in hypoxic 
MDA-MB-468. Representative immunoblots of HIF-1 (i) and HIF-2 (ii) protein 
expression after 22 hours of acute hypoxia (1% O2). Protein (30µg) was resolved 
on SDS polyacrylamide gels, transferred to nitrocellulose and probed with anti-
HIF-1, anti-HIF-2, anti-β-actin antibodies and IR-conjugated secondary 
antibodies. Immunoblotting with -actin was used to check equal protein loading 
(iii). The staining was visualised by LI-COR. Con: Control. Hyp: Hypoxic.   
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In order to investigate glycogene expression in hypoxia TNBC cells; RNA was 
extracted from control and hypoxic MDA-MB-468 cells and reverse transcribed to 
cDNA. Successful reverse transcription was shown by end-point PCR 
amplification of -actin (Figure 3.11). The NTC lane did not show amplification of 
-actin (Figure 3.11) confirming that there was not contamination.  
 
 
Figure 3.11:  Verifying cDNA synthesis from tumour RNA. End point PCR 
was used to analyse cDNA synthesis reactions from MDA-MB-468 cells following 
hypoxia (1% O2). Gel electrophoresis was used to resolve cDNA in (1x) TAE 
buffer.  Reactions contained cDNA with (+) reverse transcriptase, RNA without 
reverse transcriptase (-) and with cDNA replaced with dH2O (NTC). (L) Ladder.  
(C) Control. (H) Hypoxic. (RT) Reverse transcriptase. Rep: biological replicate.      
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3.4.13: Optimising qRT-PCR conditions in normoxic MDA-MB-468 cells.  
 
Prior to assessing gene expression, qRT-PCR conditions were optimised to 
minimise use of materials yet maintain generation of reliable high-quality qRT-
PCR data. A standard qRT-PCR contains 25ng of cDNA template and 10µM 
oligonucleotides. The qRT-PCR conditions were optimised by reducing the 
concentration of oligonucleotides from 3µM to 1.5µM (Figure 3.12). Under these 
conditions the CT value of β2M reduced from 15.45 to 13.77 (Figure 3.12). A 
similar trend was observed where the CT value decreased from 17.9 to 12.8 for 
RPLP0. While there was a reduction in the CT value with decreasing 
oligonucleotide concentration, the CT value still indicated strong expression 
without compromising results.  
In order to optimise the concentration of cDNA used per qRT-PCR, the 
concentration of cDNA was reduced from 25.0ng per reaction to 6.25ng (Figure 
3.12). As the concentration of cDNA template decreased, the CT value of each 
gene tested increased as expected (Figure 3.12). For example, in GALNT3, the 
CT value at 25ng of cDNA increased from 22.01 to 23.46 with 6.25ng cDNA. 
Although an increase in CT value was observed, gene expression remained 
strong and therefore would not compromise the data analysis. Therefore, all qRT-
PCR reactions contained 1.5µM oligonucleotides with 12.5ng of cDNA as this 
would minimise material use but still generate high-quality qRT-PCR data.  
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Figure 3.12: Optimisation of qRT-PCR reactions to assess glycogene 
expression in normoxic MDA-MB-468.  (A) The effect of altering 
oligonucleotide concentration. qRT-PCR containing 3.0 μM or 1.5 μM 
oligonucleotides and 25ng cDNA were prepared and the expression of β2M, 
RPLP0, GALNT6, GALNT7, GALNT12 and GALNTL5 analysed. (B) The effect of 
altering cDNA template concentration. qRT-PCR reactions contained 1.5 μM 
oligonucleotides and 25-6.25 ng of cDNA template and gene expression of β2M, 
RPLP0, GALNT3, GALNT6 and GALNT7 was analysed. (A+B) CT values are 
shown as the mean ± SD where n=2 technical replicates.   
87 
 
3.4.14: Validating HIF induction in hypoxic MDA-MB-468 cells. 
 
MDA-MB-468 cells exposed to acute hypoxia (1% O2) for 22 hours or grown 
under normoxia were used to assess the expression of HIF-1 and its 
downstream target carbonic anhydrase 9 (CA9) (Kuijper et al., 2005). Expression 
of HIF-2 and its downstream targets erythropoietin (EPO) and vimentin (VIM) 
(Semenza and Wang, 1992) were also analysed in hypoxic MDA-MB-468 cells 
(Figure 3.13). Surprisingly, HIF-1 and EPO expression was downregulated 
under these conditions, whilst HIF-2, CA9 and vimentin expression were 
upregulated (Figure 3.13). Despite the decreased expression of HIF-1, the 
marked increase in CA9 expression suggests that the hypoxic conditions initiated 
a hypoxic response (Figure 3.13). 
Successful induction of hypoxia within the cells was confirmed by the induction 
of HIF-1 and HIF-2 by immunoblotting (Figure 3.10). This is in keeping with the 
literature which suggests induction of HIF-1 occurs at the protein level because 
HIF-1 mRNA expression is variable (Greijer et al., 2005). As can be seen from 
the large error bars there was a degree of variation between the degree of 
hypoxic adaptation within the MDA-MB-468 biological replicates (Figure 3.13). 
HIF-1 ranged from -7.76 to -1.55-fold and HIF-2 expression varied from -3.12 
to 3.39-fold (Figure 3.13). This shows that although hypoxia was induced, the 
hypoxic conditions may not have been identical between biological replicates, 
therefore the downstream response may not have been as intense and therefore 
variation in intensity is present. Variability in the hypoxic conditions may have 
been introduced by means including that biological replicates were not exposed 
to hypoxia simultaneously. 
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Figure 3.13:  Analysing HIF induction in hypoxic MDA-MB-468. (A) The fold 
change in gene expression of hypoxia inducible factors HIF-1 and HIF-2 and 
downstream targets CA9, EPO and VIM were analysed in hypoxic MDA-MB-468 
cells by qRT-PCR. Data was normalised to the geometric mean of β-actin, β2M 
and RPLP0. Fold change in gene expression is shown as the mean ± SEM where 
n=4 biological replicates. The dotted line represents basal (i.e unperturbed) gene 
expression.  
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3.4.15: Validating altered glycogene expression in hypoxic MDA-MB-468 
cells. 
 
Following the successful induction of hypoxia in MDA-MB-468 cells, the 
expression of 11 glycogenes (GALNT3, 6, 7, 12, 14, L5, B3GNT2, B4GALT2-3, 
NEU1 and NEU3) was assessed in response to hypoxia as these genes showed 
the most intense induction in the tumour samples analysed. Surprisingly, 
GALNTL5 was the only glycogene that was upregulated in hypoxic MDA-MB-468 
cells whilst expression of GALNT6, GALNT14 and NEU3 was downregulated. 
B3GTN2, B4GALT2, B4GALT3, GALNT7, GALNT12 and NEU1 expression 
remained unchanged (Figure 3.14). Results of these analyses suggest that 
mRNA levels of GALNTL5, GALNT6, GALNT14 and NEU3 differ in hypoxic MDA-
MB-468 cells compared to control cells and furthermore, that hypoxia and 
possibly HIF-1/HIF-2 may be regulating expression of glycosylating enzymes.  
  
90 
 
 
 
Figure 3.14: Analysing glycogene expression in hypoxic MDA-MB-468 cells. 
(A) The fold change in gene expression of glycogenes B3GNT2, B4GALT2, 
B4GALT3, GALNT3, 6, 7, 12, 14 L5, NEU1 and NEU3 was analysed in hypoxic 
MDA-MB-468 cells by qRT-PCR. Data was normalised to the geometric mean of 
β-actin, β2M and RPLP0. Fold change in gene expression is shown as the mean 
± SEM where n=4 biological replicates. The dotted line represents basal (i.e 
unperturbed) gene expression. 
 
3.4.16: Correlating HIF induction with glycogene expression under hypoxia 
in MDA-MB-468 cells. 
 
As a result of the glycogene and HIF expression analyses in hypoxic MDA-MB-
468 cells, a correlation in expression trends was observed. Furthermore, variation 
in the induction of hypoxia seemed to correlate with the induction of target 
downstream expression (Figure 3.15). Interestingly, the fold change in gene 
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expression of B4GALT2, GALNTL5 and NEU1 seemed to correlate with the level 
of HIF-1 and HIF-2 induction (Figures 3.15 and 3.16). The replicates which 
demonstrated strong HIF-1 or HIF-2 induction also had strong B4GALT2, 
GALNTL5 and NEU1 expression. Where HIF-1 or HIF-2 expression was not 
as intense, induction of B4GALT2, GALNTL5 and NEU1 was decreased. 
Currently there are no links between B4GALT2, GALNTL5, NEU1 and either HIF-
1 or HIF-2 established in the literature.  
The correlation between the level of HIF induction and glycogene expression in 
TNBC tumours 11004, 10046, 10076 and hypoxic MDA-MB-468 cells suggests a 
possible link between transcription of these glycosylation genes and induction of 
HIF-1 and HIF-2. Extrapolating from this, it would be expected that there would 
be an impact on the glycosylation profile and tumour aggression in hypoxic 
TNBC. 
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Figure 3.15: The variability of HIF induction in hypoxic MDA-MB-468 cells. 
The fold change in gene expression of HIF-1, HIF-2 and downstream targets 
genes CA9, EPO and VIM was analysed in hypoxic MDA-MB-468 cells by qRT-
PCR. Fold change in gene expression of each biological replicate was normalised 
to the geometric mean of β-actin, β2M and RPLP0. The dotted line represents 
basal (i.e unperturbed) gene expression. 
  
1 2 3 4
-10
-8
-6
-4
-2
0
HIF-1
Replicate
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
1 2 3 4
-4
-2
0
2
4
HIF-2
Replicate
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
1 2 3 4
0
2
4
6
8
10
50
60
CA9
Replicate
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
1 2 3 4
-20
-10
-5
0
5
EPO
Replicate
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
1 2 3 4
-2
0
2
4
6
8
VIM
Replicate
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
A) B)
C) D)
E)
93 
 
 
Figure 3.16: The variability of glycogene expression in hypoxic MDA-MB-
468 cells. 
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Figure 3.16 continued: The variability of glycogene expression in hypoxic 
MDA-MB-468 cells. The fold change in gene expression of glycogenes B3GNT2, 
B4GALT2, B4GALT3, GALNT3, 6, 7, 12, 14, L5, NEU1 and NEU3 was analysed 
in hypoxic MDA-MB-468 cells by qRT-PCR. Fold change in gene expression of 
each biological replicate was normalised to the geometric mean of β-actin, β2M 
and RPLP0. The dotted line represents basal (i.e unperturbed) gene expression.
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3.4.17: Determining the glycan profile of hypoxic MDA-MB-468. 
 
The glycosylation profile of TNBC is altered compared to control and in response 
to hypoxia and the above data suggests that the hypoxic tumour environment 
may alter glycogene expression. Furthermore, this may have an impact or 
corresponding change to the glycosylation profile of hypoxic TNBC cells. To 
assess this, lectins were used to detect different sugar moieties. Lectins were 
chosen based on their sugar specificities, covering a wide range of sugars. 
Hypoxic MDA-MB-468 cells were stained with biotinylated lectins (PNA, DBA, 
PHA-E, RCA, LCA and WGA) and analysed by flow cytometry.  
 
3.4.17: The impact of lectin staining on cell size and granularity in hypoxic 
MDA-MB-468. 
 
Forward scattering indicates cell size whilst side scatter indicates the cell’s 
granularity (Tzur et al., 2011). Hypoxia did not alter cell size or granularity in 
unstained control or hypoxic MDA-MB-468 cells. Similarly, the addition of PE-
streptavidin to control and hypoxic cells did not significantly affect cell size or 
granularity (Figure 3.17).  
Staining of cells with PNA increased cell size from 309 to 376 under hypoxic 
conditions. Cells stained with DBA also exhibited an increase in cell size under 
hypoxia (313 to 392). This increase in cell size in hypoxic cells was observed 
when staining with lectins PHA-E, LCA and RCA where cell sizes increased from 
403 to 416, 425 to 439 and 412 to 419, respectively (Figure 3.17A). 
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Hypoxic cells stained with PNA, PHA-E and LCA, significantly increased cell 
granularity compared to control cells. Cell granularity increased from 343 to 428 
when stained with PNA under hypoxia (p<0.05) and increased upon staining with 
PHA-E from 334 to 424 between control and hypoxic cells (p<0.05). Similarly, cell 
granularity increased from 324 to 424 when staining with LCA between control 
and hypoxic cells (p<0.01) (Figure 3.17B).  
 
 
Figure 3.17A: Investigating the lectin staining profile of hypoxic MDA-MB-
468 cells stained with lectins.  
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Figure 3.17A continued: Investigating the lectin staining profile of hypoxic 
MDA-MB-468 cells stained with lectins.MDA-MB-468 cells were exposed to 
hypoxia (1% O2) for 22 hours and stained with biotinylated lectins: PNA, DBA, 
PHA-E, RCA, LCA, WGA. Staining was detected with phycoerythrin (PE) – 
streptavidin and was analysed by flow cytometry counting 10000 gated events.  
Forward scatter (FSC-H) and side scatter (SSC-H) profiles are shown: (A) cells 
only; (B) cells and Phycoerythrin (PE); (C) Peanut agglutinin (PNA); (D) Dolichos 
biflorus agglutinin (DBA); (E) Phaseolus vulgaris erythroagglutinin (PHA-E); (F) 
Ricinis communis agglutinin (RCA); (G) Lens culinaris agglutinin (LCA); (H) 
Wheat germ agglutinin (WGA).  
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Figure 3.17B: The effect on lectin staining on cell size and granularity in 
hypoxic MDA-MB-468 cells.  MDA-MB-468 cells were exposed to hypoxia (1% 
O2) for 22 hours and stained with biotinylated lectins: PNA, DBA, PHA-E, RCA, 
LCA, WGA. Staining was detected with phycoerythrin (PE) – streptavidin and was 
analysed by flow cytometry counting 10000 gated events. Panels (A) and (B) 
show the geometric mean of forward and side scatter (n=3 biological replicates, 
mean ± SEM). Statistical analysis was performed by 2-way ANOVA with Sidak’s 
multiple comparisons where *p<0.05, **p<0.01.  
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3.4.18: The impact of lectin staining on PE-streptavidin fluorescence in 
hypoxic MDA-MB-468. 
 
In order to investigate the potential change in glycosylation profile in hypoxic 
TNBC cells to glycan structures on the cell surface, control and hypoxic MDA-
MB-468 cells were stained with lectins PNA, DBA, PHA-E, RCA, LCA and WGA 
(Figure 3.18). Fluorescence was measured by streptavidin- conjugated-
phycoerythrin (PE-streptavidin) by flow cytometry.  
In unstained control and hypoxic cells, only background fluorescence was 
observed. This was also observed in cells stained with PE only, indicating that 
PE staining was specific for the presence of lectins. Similarly, in control cells 
stained with PNA and DBA only background fluorescence was present indicating 
little binding by these lectin sugars to the surface of TNBC MDA-MB-468 cells 
(Figure 3.18). However, there was a slight rightward shift in hypoxic cells stained 
with PNA and DBA, which suggests a higher proportion of bound lectins 
compared to control cells. Cells stained with PHA-E, RCA and LCA had intense 
lectin binding compared to control cells indicating strong binding by these lectin 
sugars to hypoxic MDA-MB-468 cells.  
This data shows strong binding of PHA-E, RCA, LCA and WGA to MDA-MB-468 
cells, indicating a high proportion of complex N-type glycans, non-reducing 
terminal β-D-galactose, core fucosylated glycans and N-acetyl-neuraminidase 
residues on the surface of MDA-MB-468 cells.  This would suggest that there is 
a trend for increased N-type glycans, non-reducing terminal β-D-galactose, core 
fucosylated glycans and N-acetyl-neuraminidase glycans in hypoxic MDA-MB-
468 cells.   
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Figure 3.18: The change in lectin binding profile in response to acute 
hypoxia. (A) Representative target glycans for lectin binding. (B) MDA-MB-468 
cells were exposed to hypoxia (1% O2) for 22 hours and stained with biotinylated 
lectins: Peanut agglutinin (PNA), Dolichos biflorus agglutinin (DBA), Phaseolus 
vulgaris erythroagglutinin (PHA-E), Ricinis communis agglutinin (RCA), Lens 
culinaris agglutinin (LCA), Wheat germ agglutinin (WGA). Staining was detected 
with phycoerythrin (PE) – streptavidin and was analysed by flow cytometry 
counting 10000 gated events. The geometric mean of PE-streptavidin 
fluorescence is shown (n=3 biological replicates, mean ± SEM). The sugar 
residues detected by each lectin are shown in the key.   
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3.4.19: Conclusions.  
 
The above data suggests that glycogene expression in TNBC is altered 
compared to tissue matched controls. qRT-PCR analysis indicated that the 
expression of glycan-initiating genes, glycan-extension genes and sialidases was 
changed in tumour tissue compared to control tissue. These alterations were 
assessed in hypoxic TNBC MDA-MB-468 cells to replicate the tumour 
environment - which elucidated abnormal expression of glycogenes: GALNTL5, 
GALNT6, GALNT14 and NEU3 in hypoxic cells compared to control cells. A 
correlation between hypoxia gene expression and glycogene expression was 
observed; potentially indicating regulation. Lectin binding analysis indicated 
hypoxia significantly increased cell granularity when stained with lectins: PHA-E, 
RCA, LCA and WGA. Furthermore, a trend between hypoxia and alterations in 
terminal galactose residues, fucosylated glycans, N-type complex glycans and 
sialylated glycans in MDA-MB-468 cells was identified.  
3.5: Discussion  
 
3.5.1: Aberrant glycosylation in TNBC.  
 
TNBC is an aggressive subtype of breast cancer which lacks common receptors 
for drug targets (ER-, PR-, HER2-) (Hon et al., 2016). Due to its insensitivity to 
current clinical therapies, TNBC is currently the most difficult type of breast 
cancer to treat (Shao, Sun and Deng, 2017). This underpins the urgent need to 
identify therapeutic targets and develop effective treatments. In many solid 
tumours, areas of moderate to severe hypoxia (<60 mm Hg) arise through 
uncontrolled cell proliferation with insufficient vascularisation (Muz et al., 2015).  
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Adaptations mediated though HIFs cause changes to cell proliferation, 
angiogenesis and glucose metabolism (Annibaldi and Widmann, 2010). HIF-1 
changes the primary metabolic substrate to glucose and glutamine which are the 
basis of DNA, protein and lipid synthesis (Liberti and Locasale, 2016). This 
causes a substantial change in the levels of intracellular nucleotide sugars which 
may alter cellular functions and modify glycan structures on the cell surface 
(Shirato et al., 2011). Aberrant protein glycosylation is common in many cancers, 
including breast cancer (Hanahan and Weinberg, 2011) however, the underlying 
molecular mechanisms which facilitate these changes are poorly understood and 
therefore require further study (Venkitachalam et al., 2016).  
This chapter aimed to profile changes to glycogene expression in TNBC through 
profiler array and qRT-PCR. qRT-PCR provided a quantitative measure of 
changed gene expression in TNBC and hypoxic MDA-MB-468 cells whilst lectin 
staining, and flow cytometry assessed the impact of hypoxia on glycan structures 
in TNBC MDA-MB-468 cells.  
The data collected indicates that the glycosylation gene expression profile is 
altered in TNBC compared to tissue matched controls, that hypoxic MDA-MB-468 
cells share altered expression in some glycogenes and that the glycan profile of 
MDA-MB-468 cells is altered in some respects in response to acute hypoxia. It is 
important to acknowledge that the in vivo data present here only represents the 
changes to glycogene expression in three individual TNBC patients. To 
understand the global changes to the glycan profile of TNBC, a larger sample 
size of TNBC samples should be considered.  
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3.5.2: MDA-MB-468 cells as a model of TNBC. 
 
MDA-MB-468 cells are one of the six distinct molecular subtypes of TNBC 
(Lehmann et al., 2011). MDA-MB-468 cells are of the Basal-like 1 type and are 
enriched in cell cycle and cell division pathways and components (Lehmann et 
al., 2011).  
Since TNBCs are largely considered basal-like (Hu et al., 2006), MDA-MB-468 
cells are an adequate representation of the TNBC cell population; having been 
used in numerous TNBC studies (Goode et al., 2017; Lanning et al., 2017; Jung 
et al., 2018). Therefore, the hypoxic MDA-MB-468 cells used in this study 
provided an adequate model to study the changes to glycosylation profile of 
hypoxic TNBC.  
 
3.5.3: Glycogene expression is altered in TNBC.  
 
Glycosylation aberrations are found in breast cancer and give rise to phenotypic 
changes which aid in tumour formation and aggression (Dall’Olio and Trinchera, 
2017). The glycan structures present in breast cancer differ to those found in 
healthy tissue which are facilitated by enzymes such as GALNT, B4GALT, FUT, 
ST3GAL and MGATs (Figure 3.19). Previously, altered glycogene expression 
has been screened in cohorts of breast cancer patients (Potapenko et al., 2010). 
Such analysis indicated changes to expression in a number of genes including 
those involved in N-glycan branching, sialylation, O-glycan initiation and glycan 
extension genes including B4GALT3 (Potapenko et al.,  2010). Here, 84 key 
glycogenes were profiled in TNBC and a marked change in the glycosylation 
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profile between TNBC and control tissue was identified. For example, glycan 
extension genes: B3GLCT, B3GNT2, B4GALT1-3, C1GALT1C1, OGT and 
POMT2 were upregulated in tumour 11004 and 10046. qRT-PCR analysis of 
tumour 10076 also indicated altered expression of B3GNT2, B4GALT2 and 
B4GALT3. 
 
Figure 3.19: Sugar residues transferred to glycan structures by various 
glycogenes. Colour coding indicates which genes are responsible for the 
enzymatic addition of sugar residues. GlcNAc: N-acetylglucosamine. GalNAc: N-
acetylgalactosamine. Gal: Galactose. Fuc: Fucose. Man: Mannose. Sia: Sialic 
acid.   
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3.5.3.: O-glycan initiating gene expression and sialidase is altered in TNBC. 
 
The GALNT enzymes and sialidase enzymes are critical for the commencement 
and decoration of O-glycans (Brochhausen 2009). In this study, upregulation of 
GALNT3, GALNT4, GALNT6, GALNT7, GALNT11 and GALNT14 was observed 
in TNBC tumours 11004 and 10046 (Figures 3.5 and 3.6) and their upregulation 
has been identified in other BrCa studies (Potapenko 2010). Similarly, the 
upregulation of sialidase gene ST3GAL1 has been noted in this study as well as 
others (Albequerque 2018). 
GALNT14 specifically promotes breast cancer metastasis to the lung through the 
mediation of metastatic colonies, self-augmentation renewal of breast cancer 
cells and by overcoming the inhibitory effect of lung-derived bone morphogenetic 
proteins (Song et al., 2016). As GALNT14 was upregulated in both tumours 
analysed via array profiling - lung metastasis in the patients from tumours 11004 
and 10076 may have been observed. However, patient reports did not detail 
metastasis other than that of the auxiliary lymph node, so a direct link is unable 
to be established (Table 2.1.1). 
Due to the observed alterations in sialidase genes it is likely that there is altered 
ST antigen expression on TNBC cells (Figure 3.1) which may contribute to 
mammary carcinogenesis and promotion of truncated O-glycan structures (Picco 
et al., 2010).  In addition, NEU1, the lysosomal sialidase was upregulated in 
tumours 11004 and 10046. NEU1 forms a complex with MUC1, which is high 
glycosylated, and has been shown to facilitate metabolic reprogramming in triple 
negative breast cancer, most notably affecting glutamine dependency of the cells 
(Goode et al., 2017). Therefore, upregultion of NEU1 could lead to altered cell 
signalling, adhesion and facilitate an aggressive tumour phenotype in TNBC. 
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3.5.4: TNBC and hypoxic MDA-MB-468 do not preferentially express the 
same HIF-subunit.   
 
Triple negative breast cancer is inherently hypoxic and these hypoxic conditions 
trigger a particularly aggressive tumour phenotype (Vaupel, 2008; Gregg L. 
Semenza, 2016). Hypoxia has the potential to significantly alter cell metabolism 
and gene expression (Semenza, 2012); therefore, it has the potential to 
significantly alter TNBC tumour glycosylation. In TNBC tumour samples the 
degree of HIF1 and HIF-2 induction was assessed by qRT-PCR. HIF-1 was 
preferentially expressed whereas HIF-2 exhibited downregulation unanimously 
in all three TNBC tumours (Figure 3.9). This suggests that in TNBC tumours HIF-
1 was the key regulator of adaptations to hypoxia and therefore, changes to 
glycogene expression and glycan structures may have been a result of HIF-1. 
However, it is important to note that HIF-1 and HIF-2 may be expressed for 
short periods of time in response to varying oxygen concentrations, and as a 
result may have different timeframes (Ratcliffe, 2007). This would suggest that 
HIF-1 and HIF-2 are perhaps involved at different stages of tumourigenesis.  
In this study, hypoxic MDA-MB-468 cells were used to replicate the tumour 
environment. The cells were exposed to acute hypoxia (1% O2) for 22 hours and 
protein expression was analysed by western blotting. Both HIF-1 and HIF-2 
protein expression was observed (Figure 3.10), confirming HIF-1 and HIF-2 
pathways are activated by acute hypoxia in TNBC (Koh et al., 2011). Following 
the induction of acute hypoxia in MDA-MB-468 cells, the expression of HIF-1, 
HIF-2, CA9, EPO and VIM was analysed by qRT-PCR. Surprisingly, HIF-1 and 
EPO expression was downregulated following hypoxia. As CA9 is a downstream 
107 
 
target of HIF-1 (Wykoff et al., 2000), and was upregulated in hypoxic MDA-MB-
468 cells, this is indicative of HIF-1 transcription and induction of hypoxia and 
activation of HIF-1 signalling in these cells (Kaluz et al., 2009). Due to the short-
lived transcript of HIF-1 and the fact that HIF-1 is downregulated following 
prolonged periods of hypoxia (Huang et al., 1996),  it is entirely possible that HIF-
1 mRNA was present at one point, but was not detected at this time.  HIF-1 
and HIF-2 gene expression and protein expression were only analysed following 
22 hours of 1% O2 and therefore, the data here represents one timepoint. Hypoxic 
exposure for differing lengths of time and oxygen concentrations may have 
reported alternative levels of HIF induction.  
In hypoxic MDA-MB-468, HIF-2 was preferentially expressed (Figure 3.15). HIF-
1 and HIF-2 drive hypoxia response element (HRE) dependant gene 
transcription (Wenger, 2002), but have different functions; perhaps due 
differences in tissue specific and temporal patterns in induction of each HIF-
subunit (Rosenberger, 2002; Wiesener et al., 2003). It has been suggested that 
HIF-1 and HIF-2 have distinct transcriptional targets and therefore 
transcriptional responses of either may support a particular physiological 
adaptation to hypoxia (Rankin et al., 2007). Knockout of HIF-1 or HIF-2 in mice 
causes distinctly altered phenotypes, with knockdown of HIF-2 resulting in 
reduced growth of neuroblastoma tumours in athymic mice (Holmquist-
Mengelbier et al., 2006). HIF-1 is the dominant mediator of the acute hypoxic 
response at 1% O2, and it known to promote tumour growth, invasion, metastasis 
and therapy resistance  (Lu and Kang, 2010; Semenza, 2012). Whereas HIF-2 
is the dominant HIF regulating VEGF and other angiogenic factors in cancer 
(Rankin et al., 2007).  
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It is unclear as to why HIF-1 was predominantly expressed in TNBC tumour 
tissue whereas HIF-2 expression dominated in hypoxic MDA-MB-468 cells. It is 
possible that acute hypoxia induced (24hrs exposure to 1% O2) in this study may 
have favoured the gene expression of HIF-2 over HIF-1 in MDA-MB-468 cells. 
Furthermore, hypoxic MDA-MB-468 cells were bathed in high glucose media 
which provides the necessary nutrients for cellular metabolism however, the 
TNBC samples were likely poorly perfused due to lack of functioning vasculature; 
promoting a more hostile cellular environment which may have favoured HIF-1 
expression.   
In a number of tumours including prostate, pancreas, colorectal and clear cell 
renal carcinoma a switch between HIF-1 and HIF-2-dependent transcription 
has been reported and is thought to be due to the hypoxia associated factor 
(HAF) activity (Koh et al., 2011). HAF is an E3 ubiquitin ligase that binds to and 
ubiquitinates HIF-1 through a p-VHL independent mechanism, sending HIF-1 
for proteasomal degradation (Ohh et al., 2000). This system may have influenced 
the switch from HIF-1 to HIF-2 expression in the hypoxic MDA-MB-468 cell 
line if HIF-1 is the initially expressed subunit. Lastly, the tumour variation and 
grade must be considered regarding the preferential expression of HIF-1 in the 
TNBC samples. As documented in Table 2.1.1, tumours used in this study were 
of grade 2 and 3.  It is unknown if the induction of hypoxia is altered throughout 
tumour stages, but it could be suggested that as the tumour growth progressed, 
a switch in HIF-2 to HIF-1 induction may have occurred.  
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3.5.5: Inter-individual tumour variation.  
 
Despite tumours 11004, 10046 and 10076 being classified as TNBC, 
interindividual variation still exists between these patients. For example, the 
ethnicities of each women are unknown, and may be a factor in the discrepancies 
in gene expression identified between each tumour.  TNBC is more common in 
women with African ancestry than women of other ethnic origins (Bauer et al., 
2007). Black women with late-stage TNBC present with the poorest 5 year 
relative survival of only 14% compared to approximately 37% for non-Hispanic 
white and Hispanic women (Bauer et al., 2007). It could be suggested that 
tumours 11004 and 10046, which share a high proportion of the altered 
glycogene expression identified here, could be of the same race and therefore; 
share common gene aberrations.  
In addition, the depth at which the tumour biopsy was taken at for each individual 
is not established. This factor could influence the degree of hypoxia found within 
each tumour sample and therefore the induction of HIF and subsequent changes 
to glycogene expression. This is due to the decrease in oxygen perfusion to each 
cancer cell at increasing distance from the nearest capillary (Tannock, 2001). 
 
3.5.6: HIFs may drive glycogene expression in TNBC and hypoxic MDA-MD-
468 cells.  
 
Through qRT-PCR analysis of TNBC tumour samples, it was identified that HIF-
1 expression correlated with the expression of glycogenes: GALNT3, GALNT6, 
GALNT7, GALNT12, B3GNT2, B4GALT2, B4GALT3, NEU1 and NEU3 (Figures 
3.7 to 3.9). In addition to this, the expression of GALNTL5 was found to correlate 
110 
 
with HIF-2 induction in tumours 11004, 10046 and 10076 (Figures 3.7 and 3.9). 
This suggests a possible correlation between HIF-1 and HIF-2 expression and 
glycogene expression in TNBC - which has not been shown before. These trends 
were also observed in hypoxic MDA-MB-468 cells where the expression of 
B4GALT2, GALNTL5 and NEU1 correlated with the induction of HIF-1 and HIF-
2 (though HIF-2 was predominantly expressed) (Figures 3.15 and 3.16). 
Although HIF-1 and HIF-2 share some target genes, they do have separate 
functions and target genes (Menrad et al., 2010) so, this was interesting that they 
mediated expression of shared glycogenes. This could be linked to the different 
timeframes of HIF-1 and HIF-2 expression (Ratcliffe, 2007) and that 
glycosylation is a sequential process that does not occur at one single timepoint 
(Bieberich, 2014). Changes in glycogene expression may correlate with the 
induction of HIF-1 or HIF-2 when they become activated, and subsequently, 
prevent or promote the expression of selected glycogenes and therefore; glycan 
structures.  
In both TNBC tumour tissue and the hypoxic MDA-MB-468 cells, B4GALT2 and 
NEU1 expression correlated with the predominantly expressed HIF subunit (i.e 
to HIF-1 in TNBC, but HIF-2 in hypoxic MDA-MB-468 cells) - suggesting that 
B4GALT2 and NEU1 may be mediated by either or both HIFs. Conversely, only 
O-glycan initiating genes GALNT3, 6, 7, and 12 expression correlated with HIF-
1 in the TNBC tumour tissue. Similarly, the glycan-extension enzymes B3GNT2 
and B4GALT3 and the sialidase NEU3 also only correlated with HIF-1 in the 
TNBC tumour tissue. This indicates that GALNT3, 6, 7, 12, B4GALT3 and NEU3 
may facilitate traits attributable to the aggressive role of HIF-1 in breast cancer 
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including: altered metabolism, metastasis and radiotherapy-resistance (Gilkes 
and Semenza, 2013). This link has not been proposed before in the literature.  
GALNTL5 was the only gene which was found to correlate with HIF-2 
expression in both the tumour tissue and hypoxic MDA-MB-468 cells. This may 
indicate that GALNTL5 may play more of a role in tumour angiogenesis, growth 
or cell proliferation – factors more characteristic to the HIF-2 subunit. Currently, 
there is no evidence linking expression of GALNTL5 to breast cancer, or TNBC 
so these findings are novel.   
These results taken together indicate that the hypoxic tumour microenvironment 
may significantly impact on protein glycosylation due to metabolic changes, 
availability of nucleotide sugars and glycogene expression to alter the 
glycosylation profile of TNBC cells. In turn, these hypoxia-driven changes to the 
TNBC glycosylation profile may impact cell-cell interactions, cell adherence, 
invasion and growth (Varki and Lowe, 2009); thus leading to a highly aggressive 
tumour phenotype.  
 
3.5.7: Lectin staining affects cell granularity in hypoxic MDA-MB-468 cells.  
 
Altered glycosylation of glycoproteins and glycolipids is a common occurrence in 
malignant transformation. In some cancers changes to cell surface glycans have 
been observed and correlate with poor patient prognosis (Dennis, Granovsky and 
Warren, 1999). This is particularly prevalent with the expression of the STn 
antigen in breast cancer (Figure 3.1) which is an indicator of resistance to 
adjuvant chemotherapy (Miles et al., 1994) 
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Lectins have previously been used to investigate the relationship between 
membrane RCA binding and the metastatic capability of TNBC cells (Zhou et al., 
2015) where membrane-positive staining of RCA was most observed in late-
stage rather than early-stage cancers (Zhou et al., 2015).In this study, hypoxic 
MDA-MB-468 cells were stained with biotinylated lectins to elucidate changes to 
lectin-glycan binding upon hypoxic exposure. Analysis of flow-cytometry results 
indicated that hypoxia increased cell size and cell granularity. After hypoxic 
exposure, it was evident that the morphology of hypoxic cells was altered. Cells 
exposed to acute hypoxia appeared to be flat, larger and displayed vacuolization 
(data not shown). Vacuolization is an indicator of cellular senescence and 
autophagy and therefore staining with β-galactosidase would serve as a positive 
indicator of senescence (Chen et al., 2018) while cell autophagy can be detected 
by LC3 immunostaining (Rosenfeldt et al., 2012). Interestingly, there are many 
genes involved in the cell cycle and glycolysis that are regulated by HIFs and are 
associated with cellular senescence (Welford and Giaccia, 2011). 
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Figure 3.20: Examples of glycan synthesis indicating lectin binding 
regions. Square brackets indicate lectin binding regions to sugar residues.  
GlcNAc: N-acetylglucosamine. GalNAc: N-acetylgalactosamine. Gal: Galactose. 
Fuc: Fucose. Man: Mannose. Sia: Sialic acid.   
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3.5.8: Hypoxic MDA-MB-468 cells show differential lectin binding. 
 
GALNT enzymes catalyse the addition of an N-acetylgalactosamine (GalNAc) to 
a serine or threonine residue during O-glycan synthesis (Fu et al., 2016). qRT-
PCR analysis indicated an increase in expression of GALNT3 and GALNTL5, but 
a decrease in expression of GALNT6, GALNT7, GALNT12 and GALNT14 in 
hypoxic MDA-MB-468 cells (Figure 3.14). This may account for minimal binding 
of the lectin DBA as it binds to terminal N-acetylgalactosamine residues (Figure 
3.20) (Ogino et al., 1999). However, it must be noted that N-acetylgalactosamine 
is not usually a terminated monosaccharide and is more typical of a core 
structural element of O-glycans (Mulloy, Hart and Stanley, 2009). 
Characteristically, N-acetylgalactosamine is capped by sialic acid residues 
(Brooks and Carter, 2001) or is extended by glycosyltransferases: B3GNT2, 
B4GALT1, 2, and 3 which add galactose residues to GalNAc or GlcNac (Figure 
3.19). This may justify the lack of binding of DBA to control and hypoxic cells as 
N-acetylgalactosamine residues simply may not exist in high numbers in the 
terminal form in MDA-MB-468 cells.  Furthermore, the decrease in expression of 
B4GALT2 and B4GALT3, which catalyse the addition of galactose and GlcNAc 
residues to glycans,  may have influenced the lack of binding of PNA (which binds 
to galactose) (Figure 3.20) to hypoxic cells (Mérant et al., 2005).  
 
3.5.9: Hypoxic MDA-MB-468 cells have a high proportion of complex N-
glycans. 
 
Staining of MDA-MB-468 cells with PHA-E showed strong binding in both control 
and hypoxic cells. PHA-E binds to complex N-type glycans and specifically has a 
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high affinity for galactosylated N-glycans which bisect with N-acetylglucosamine 
(Figure 3.20) (Nagae et al., 2014). The formation of this type of glycan is 
catalysed by the MGAT enzymes, most commonly by MGAT3. Unfortunately, the 
MGAT genes were not analysed in MDA-MB-468 cells due to time limitations, 
however these genes were examined in tumour samples 11004 and 10046. Array 
profiling indicated that MGAT3 was upregulated in tumour 11004 compared to its 
tissue matched control. However, gene expression of MGAT3 remained 
unchanged in tumour 10046 possibly because tumour 10046 was only of grade 
2 as opposed to the grade 3 tumour 11004 (Table 2.1.1).  In order to correlate 
the high level of binding of PHA-E to MDA-MB-468 cells, qRT-PCR analysis of 
MGAT3 in both control and hypoxic cells should be investigated. Extrapolating 
from the PHA-E lectin binding observed here, high expression of MGAT3 in 
hypoxic cells would be expected upon qRT-PCR analysis.  
 
3.5.10: Downregulated B4GALT2 and B4GALT3 gene expression may 
correlate with decreased RCA binding in hypoxic MDA-MB-468 cells. 
 
The lectin RCA showed intense binding in both control and hypoxic cells, with a 
slightly weaker PE-streptavidin signal in hypoxic cells (Figure 3.18). RCA binds 
to reducing terminal β-D-galactose residues (Figure 3.20) (Wang et al., 2011) 
suggesting a decrease in galactose in hypoxic cells. During the formation of type-
2 glycan LacNAc (N-acetyllactosamine) chains, terminal N-acetylglucosamine 
residues are usually galactosylated (Stanley and Cummings, 2015). This reaction 
is catalysed by glycan-extension enzymes B4GALT1, 2, 3, 4, 5, and 6 which form 
N-acetyllactosmaine units (Figure 3.19) (Stanley and Cummings, 2015). qRT-
PCR analysis of B4GALT2 and B4GALT3 in hypoxic MDA-MB-468 cells indicated 
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a slight decrease in expression which would correlate with the RCA binding found 
here (Figure 3.18). Alternatively, the galactose residue may have been capped 
by sialic acid, therefore inhibiting RCA binding. Cell surface glycan-sialylation has 
been shown to block the binding of pro-apoptotic galectins in colon cancer; 
promoting tumour cell survival (Zhuo, Chammas and Bellis, 2008). It could be 
suggested that a parallel mechanism would occur TNBC cells, having similar 
effects.  
 
3.5.11: Hypoxia may increase core fucosylated glycans in MDA-MB-468 
cells.  
 
The lectin LCA has a strong binding affinity to core fucosylated glycans and is a 
well-documented marker for the diagnosis and prognosis of some cancers 
(Tateno, Nakamura-Tsuruta and Hirabayashi, 2009). Results of LCA staining 
demonstrated a trend for increased binding to hypoxic MDA-MB-468 cells, 
suggesting that hypoxia may increase the number of core-fucosylated glycans in 
MDA-MB-468 cells (Figure 3.18). Core fucosylation is achieved through the 
enzymatic activity of FUT8 (Yang et al., 2017). Expression of FUT8 in hypoxic 
MDA-MB-468 cells was not determined - however, FUT8 expression was 
analysed in TNBC tumours 11004 and 10046 where expression was upregulated 
in both tumours compared to tissue matched controls (Figure 3.7). To accurately 
determine if the stronger binding of LCA to hypoxic cells was a result of 
upregulation of FUT8, control and hypoxic MDA-MB-468 cells should be analysed 
by qRT-PCR. However, from the lectin-binding analysis results, upregulation of 
FUT8 in hypoxic MDA-MB-468 cells would be expected. FUT8 has previously 
been investigated in breast cancer, where it was shown to increase migratory and 
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invasive abilities of several breast carcinoma cell lines, including MDA-MB-231; 
this was determined through Transwell assay with and without Matrigel coating 
(Tu et al., 2017). With consideration to the increase in core fucosylated glycans 
observed here, the invasiveness of TNBC cells may be augmented.  
 
3.5.12:  Sialylation is decreased in Hypoxic MDA-MB-468 cells.   
 
WGA has an affinity for N-acetylglucosamine and sialic acid residues (N-
acetylneuraminic)  (Goldstein, Winter and Poretz, 1997) (Figure 3.18). qRT-PCR 
analysis of the sialic acid cleaving neuraminidases NEU1 and NEU3 (Juge, 
Tailford and Owen, 2016) in MDA-MB-468 cells, found that these genes were not 
upregulated by hypoxia (Figure 3.14). WGA binding to hypoxic MDA-MB-468 
cells was less intense than in control cells, suggesting that there are a lower 
proportion of sialic acid residues in hypoxic cells. This does not correlate with the 
general downregulation of sialidase enzymes NEU1 and NEU3, as we would 
expect there to be a larger proportion of sialic acid residues in hypoxic cells, due 
to a lack of cleavage, and therefore an increase in WGA binding. As WGA has 
affinities to galactose and GlcNAc residues and does not exclusively bind to sialic 
acid residues (Cummings and Etzler, 2009) (Figure 3.20); further assessment of 
the degree of sialyation of hypoxic MDA-MB-468 cells should be conducted with 
lectins SNA and MAH, which are more specific (Shibuya et al., 1987; Wang and 
Cummings, 1988). However, increased WGA binding may be observed at other 
timepoints and lengths of hypoxic exposure. 
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3.5.13: Conclusions and future work. 
 
The work undertaken in this study aimed to elucidate changes to the glycosylation 
profile of TNBC, as a result of altered expression of glycosylation genes. In doing 
so, a greater understanding of the cellular glycome of TNBC has been gathered. 
Here, identification of changed glycogene expression has been illuminated in 
TNBC and will aid in the identification of disease biomarkers for better treatment 
options. Understanding the mechanisms involved in altered glycogene 
expression in TNBC and how this affects cell surface glycans is crucial. The 
results found here provides evidence that TNBC and hypoxic MDA-MB-468 cells 
do in fact show differentially expressed glycogenes and that hypoxia potentially 
influences the binding of some lectins to cell surface glycans. This indicates that 
altered glycogene expression due to hypoxia causes aberrant glycosylation and 
provokes a change to the cellular glycocalyx in TNBC.  
This study has uncovered that TNBC preferentially expresses HIF-1 whereas 
hypoxic MDA-MB-468 cells mainly express HIF-2. A correlation between 
glycogene expression and the induction of HIF-1 and HIF-2 was found, where 
the expression of glycogenes from the O-glycan initiating, glycan-extension and 
sialidase family correlate with HIF-1 in TNBC or with HIF-2 in hypoxic MDA-
MB-468 cells.  
Future work should include the validation of several other genes in both TNBC 
samples 11004, 10046 and 10076, depending on the remaining resources, and 
hypoxic MDA-MB-468 cells. These genes including MGAT3, MGAT5, ST3GAL1 
and FUT8, for example. These aforementioned genes play crucial roles in 
synthesis of galactosylated N-glycans, maturation of N-glycans, the expression 
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of the ST antigen (Figure 3.1) on TNBC cells and core fucosylation of N-glycans. 
These findings would add the growing body of evidence presented here and 
establish their importance in the altered glycosylation profile of TNBC. 
In addition, it would advantageous to gauge changes to cell glycosylation at 
different exposure timepoints to hypoxia including 2, 4, 8 and 48 hours. This will 
allow the mapping of changes in glycogene expression with increasing hypoxic 
exposure and degree of HIF induction. Furthermore, it may be of interest to 
modulate the degree of hypoxia by selecting various gas mixtures including 
<0.01% and 5% oxygen to replicate anoxic tumour tissue and adjacent tumour 
tissues (Favaro et al., 2011) and the effect on glycogene expression.   
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Chapter 4: The influence of hypoxia inducible factors on 
glycogene expression in hypoxic TNBC MDA-MB-468 cells. 
 
4.1: Introduction.  
 
4.1.1: Oxygenation of tumour tissue. 
 
In rapidly proliferating and expanding tumours, oxygen demand increases and 
surpasses supply, resulting in an progressively hypoxic milieu (Semenza, 2000). 
In breast tissue, the normal tissue oxygen concentration is approximately 8% 
however, the oxygen concentration of breast cancer tissue is dramatically 
reduced to approximately 1.5% (Vaupel, Höckel and Mayer, 2007). Adaptation to 
hypoxia drives the upregulation of angiogenic factors (VEGF) from hypoxic areas 
of the tumour which promotes vascularisation (Semenza, 2012). However, these 
new blood vessels are poorly formed and are prone to leakage and collapse 
causing local tissue oedema. Consequently, tumours are filled with areas of mild 
to severe hypoxia and necrosis (Semenza, 2012).  
 
4.1.2: Hypoxia inducible factors. 
 
Hypoxia inducible factors (HIFs) are master regulators of oxygen homeostasis 
and play a critical role in hypoxic adaptation (Semenza, 2000). There are three 
HIF- subunits: HIF-1, HIF-2 and the lesser documented HIF-3 (Hu et al., 
2003). Regulation of HIF activity occurs on multiple levels (Semenza, 2000). 
Under normal oxygen concentrations, hypoxia inducible factor- (HIF-) is bound 
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tightly by the von Hippel-Lindau (VHL) protein which facilitates ubiquitination of 
HIF- and its subsequent proteasomal degradation (See Figure 1.5) (Kaelin and 
Ratcliffe, 2008). Binding of VHL is dependent upon the hydroxylation of proline 
residues in HIF- by the prolyl hydroxylases  (PHD) (Epstein et al., 2001). Three 
HIF prolyl hydrolases have been identified (PHD1-3), all three isoforms operate 
in a non-redundant manner to the regulation of both HIF-1 and HIF-2 and 
contribution of each isoform is dependent on the abundance of the enzyme 
(Appelhoff et al., 2004).  
This HIF-/VHL complex uses oxygen and -ketoglutarate as a substrate and 
therefore, its activity is inhibited under hypoxic conditions (Epstein et al., 2001). 
Henceforth, under hypoxic conditions, hydroxylation and ubiquitination of HIF 
does not occur and the subunit becomes stabilised for transcription of target 
genes (See Figure 1.5).  HIF-1 and HIF-2 share a common structures and 
target genes such as the angiogenic factor, VEGF  (Keith, Johnson and Simon, 
2011) (Figure 4.1). 
 
4.1.3: HIF-1 and HIF-2 interplay.  
 
In breast cancer cell lines, HIF-1 and HIF-2 are differentially expressed 
however, both proteins regulate arms of the hypoxic pathway (Blancher et al., 
2000) (Figure 4.1). HIF-1 plays a crucial role in tumour adaptation to changes 
in O2 concentration through the transcriptional regulation of over 100 downstream 
genes (Semenza, 2001). Genes involved in glucose metabolism (GLUT1 and 
GLUT3) and pH maintenance (CA9) are all regulated by HIF-1.  HIF-2 
activation of target genes promotes growth and metastasis in later stages of BrCa 
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and is associated with a more aggressive BrCa phenotype (Holmquist-
Mengelbier et al., 2006). HIF-2 promotes the expression of transcription of 
target genes including vimentin, which is associated with poor prognosis 
(Hemalatha, Suresh and Harendra Kumar, 2013) (Figure 4.1).   
EPO is less selective with regards to its transcriptional upregulation, with reports 
of regulation by both HIF-1 and HIF-2 (Semenza and Wang, 1992; Rankin et 
al., 2007). However, EPO is thought to be dominantly dependent on HIF-2 rather 
than HIF-1 (Rankin et al., 2007) (Figure 4.1). Furthermore,  the angiogenic factor 
VEGF is under the transcriptional control of both HIF-1 an HIF-2 which aids in 
adaptation to hypoxia via the formation of new blood vessels (Shweiki et al., 
1992). 
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Figure 4.1: HIF-1 and HIF-2 regulate distinct batteries of target genes. 
Downstream regulation of target genes by HIF-1 and HIF-2 under 
hypoxia.  HIF-1 and HIF-2 share regulation of several genes and also control 
the regulation of distinct subsets of target genes (Hu et al., 2003; Koh and Powis, 
2012). Figure adapted from (Martín-Aragón Baudel et al., 2017).  
 
4.1.4: Hypoxic regulation of glycosylation. 
 
The mechanism through which hypoxic tumour microenvironments alter cell 
glycosylation patterns is not clear.  HIF-1 controls the transcription of batteries 
of genes which aid in the adaptation to hypoxic stress including the altered 
metabolism which is observed in breast cancer (López-Barneo, Pardal and 
Ortega-Sáenz, 2001). Energy metabolism is one of the many alterations found in 
breast cancer, due to HIF-1 expression (Semenza, 2010). In growing tumour 
tissue, HIF-1 facilitates the shift from oxidative phosphorylation to aerobic 
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glycolysis in order to maintain energy production (aka Warburg effect) (Warburg 
et al., 1956). As a result, hypoxic cells metabolise more glucose in order to meet 
their energy needs. HIF-1 mediates this metabolic conversion partly through the 
expression of glucose transporters GLUT1 and GLUT3 (Denko, 2008) as well up 
the upregulation of glycolytic enzymes. Therefore, expression of glucose 
transporters, glycolytic enzymes is altered causing a dramatic shift in the cell 
metabolism (Shirato et al., 2011). In addition, altered glucose metabolism impacts 
some glycosylation genes, nucleotide sugars and transporters (Shirato et al., 
2011). An excess or surplus of nucleotide sugars can result in altered 
glycosylation due to their importance in glycan synthesis (Taniguchi, 2007).  
It remains unknown if there is a link between the expression of the transcription 
factors HIF-1 and HIF-2, and the regulation of glycosylation. In Chapter 3, HIF-
1 expression correlate with expression of several glycogenes from the O-
glycan-initiating, glycan extension and sialidase families in TNBC. Furthermore, 
expression of GALNTL5 was found to correlate with HIF-2 induction in TNBC. 
In hypoxic MDA-MB-468 cells B4GALT2, GALNTL5 and NEU1 expression 
correlated with induction of HIF-1 and HIF-2. This suggests a relationship 
between HIF-1 and HIF-2 and glycogene expression in hypoxic TNBC – which 
has not previously been investigated.  
In this chapter, the role of HIF-1 and HIF-2 in regulating glycogene expression 
was investigate by suppressed using siRNAs in hypoxic TNBC MDA-MB-468 
cells. Attenuation of HIF protein expression was determined by immunoblotting 
and the relative expression of HIF-1, HIF-2, their respective target genes: CA9 
and EPO and glycogenes GALNT3, 6, 7, 12, 14, L5, B3GNT2, B4GALT2-3, NEU1 
and NEU3 were analysed by qRT-PCR. 
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4.2: Aims 
 
Aim 1: To suppress the expression of hypoxia inducible factors, HIF-1 and HIF-
2 in hypoxic MDA-MB-468 cells using siRNA and assess the impact of 
suppression on glycogene expression.  
 
4.3: Research Questions 
 
RQ1: Is glycogene expression in hypoxic TNBC correlated with specific arms of 
the hypoxic adaptation machinery? 
 
RQ2: Does the knockdown of HIF-1 or HIF-2 in hypoxic MDA-MB-468 cells 
alter the expression of O-glycan initiating, glycan-extension and sialidases gene 
families?   
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4.4: Results 
 
4.4.1: Optimising transfection conditions for HIF-1 and HIF-2 siRNA 
knockdown 
 
In order to investigate the trend in expression between HIF-1, HIF-2 and a 
selection of glycogenes, targeted siRNAs were used to knockdown HIF-1, HIF-
2 mRNA expression in hypoxic MDA-MB-468 cells. Published siRNA 
sequences, concentrations and knockdown conditions were employed (Pawlus 
et al., 2012; Pawlus, Wang and Hu, 2014). 
The lipid transfection reagent used in this study has been show to suppress HIF-
1 and HIF-2 in TNBC cells lines, including MDA-MB-231 cells, without cell 
toxicity (Li et al., 2011; Pawlus et al., 2012). It was important to confirm this was 
the case in this model and optimise the volume of transfection reagent used to 
achieve maximum gene knockdown efficiency (Montoya and Azorsa, 2016). Cells 
were therefore treated with 6 µL HiPerfect Transfection reagent and exposed to 
acute (1% O2) hypoxia for 22 hours and HIF1/2 expression was assessed by 
immunoblotting. Immunoblotting confirmed that 6µL of HiPerfect transfection 
reagent did not cause adverse cell death or affect stabilisation of HIF-1, HIF-2 
expression in hypoxic MDA-MB-468 cells (Figure 4.2) and therefore, would be 
acceptable to use for further experiments.  
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Figure 4.2: Transfection reagent does not prevent HIF stabilisation in 
hypoxic MDA-MB-468 cells. Representative Immunoblots (N=4 biological 
replicates) of HIF-1 and HIF-2 protein expression following 22 hours of acute 
hypoxia (1% O2) and addition of transfection reagent. Protein (30 µg) was 
resolved on SDS-polyacrylamide gels, transferred to nitrocellulose and probed 
with anti-HIF-1 (i) and anti-HIF-2 (ii), anti-β-actin and IR conjugated secondary 
antibodies. Immunoblotting with β-actin was used to assess equal protein loading 
(iii). Staining was visualised by LI-COR. C: Control. TR: Transfection Reagent.  
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4.4.2: Optimising siRNA concentration conditions for HIF-1 and HIF-2 
knockdown. 
 
siRNAs towards HIF-1 and HIF-2 has been shown to create effective 
knockdown of HIF at 10 nM (Pawlus, Wang and Hu, 2014). Here MDA-MB-468 
TNBC cells were treated with 10nM siRNA towards either HIF-1 or HIF-2 then 
exposed to acute hypoxia (1% O2, for 22 hours).  siRNA knockdown, and 
specificity of knockdown, was determined by immunoblotting for HIF-1 and HIF-
2 (Figure 4.3). Optimisation was required because the siRNAs used by others 
were in MDA-MB-231 cells and therefore, it was unknown is the concentrations 
used by others would cause sufficient knockdown here (Pawlus, Wang and Hu, 
2014). It was important to determine the siRNA specificity in order to attribute 
each treatment to its effect on glycogene expression, which was later determined.  
Following establishment of transfection conditions, knockdown was examined by 
immunoblotting.  Control reactions included normoxic cells which did not show 
expression of HIF proteins and hypoxic cells without siRNAs treatment which HIF-
1 and HIF-2 were expressed, as expected.  A non-targeting scrambled control 
siRNA was implemented which did not supress the expression of either HIF-1 
or HIF-2 in the hypoxic MDA-MB-468 cells. Finally, a transfection reagent only 
control confirmed that the transfection reagent itself did not affect protein 
expression or induce cell toxicity (Figure 4.3).   
HIF-1 showed weak suppression with 10nM HIF-1 siRNA treatment, however 
complete specificity could not be determined as the protein was not entirely 
supressed (Figure 4.3). HIF-2 protein expression remained intact with 10nM 
HIF-2 siRNA treatment prompting further optimisation.   
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Figure 4.3: Assessing HIF-1 and HIF-2 protein expression following 
siRNA knockdown in hypoxic MDA-MB-468 cells. Representative 
immunoblots (n=2 biological replicates) of (i) HIF-1 and (ii) HIF-2 protein 
expression after HIF-1 and HIF-2 knockdown with 10nM siRNAs following 
exposure to 22 hours of acute hypoxia (1% O2). Protein (30 µg) was resolved on 
SDS-polyacrylamide gels, transferred to nitrocellulose and probed with anti-HIF-
1 and anti-HIF-2, anti-β-actin and IR conjugated secondary antibodies. 
Immunoblotting with β-actin was used to assess equal protein loading (iii). 
Staining was visualised by LI-COR. C: Control. TR: Transfection Reagent. Sc: 
Scrambled non-targeting siRNAs. H1: HIF-1 siRNA. H2: HIF-2 siRNA.  
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The concentration of siRNAs used was increased 25nM and 50nM to cover a 
range of concentrations. siRNAs at a the highest concentration of 50nM were 
used as this proved sufficient in the suppression of HIF-1 in MDA-MB-231 breast 
cancer cells (Soleymani Abyaneh et al., 2017).  
HIF-1 protein expression showed a 3.3-fold knockdown with 10nM HIF-1 
siRNA treatment whilst with 25nM siRNAs, HIF-1α protein expression was 
suppressed by 3.4-fold compared to the loading control. Treatment with 50nM 
HIF-1 siRNAs resulted in a 3.7-fold reduction in HIF-1 protein expression 
(Figure 4.4). HIF-2 protein expression was reduced by 1.3-fold with 10nM 
siRNAs which increased to a 3.9-fold reduction with 25nM siRNA treatment. The 
use of 50nM siRNAs on HIF-2 only produced a 2-fold reduction in the protein 
expression of HIF-2, compared to the loading control (Figure 4.4). This 
prompted further optimisation including an increase in amount of transfection 
reagent used from 6 µL to 12 µL. 
During siRNA optimisation, increasing the volume of transfection reagent 
promoted adequate HIF-2 protein knockdown in the presence of 50 nM siRNAs 
and expression was suppressed by 1.9-fold compared to the loading control 
(figure 4.5). Surprisingly an increase in HIF-1 protein expression was observed 
with HIF-2 siRNAs (Figure 4.5). The β-actin loading control showed that protein 
was loaded equally meaning protein expression of HIF-1 and HIF-2 was 
comparable. Furthermore, complete suppression of HIF-1 with 50nM HIF-1 
siRNA treatment was observed here (Figure 4.5). 
  
131 
 
 
 
Figure 4.4: Optimising siRNA treatment in hypoxic MDA-MB-468 cells. 
Immunoblots of (i) HIF-1 and (ii) HIF-2 protein expression after HIF-1 and 
HIF-2 knockdown with siRNAs (10nM, 25nM, 50nM) following exposure acute 
hypoxia (1% O2) where n=1. Protein (30µg) was resolved on SDS-polyacrylamide 
gels, transferred to nitrocellulose and probed with anti-HIF-1 and anti-HIF-2, 
anti-β-actin and IR conjugated secondary antibodies. Immunoblotting with β-actin 
was used to assess equal protein loading (iii). Staining was visualised by LI-COR 
and densitometry was analysed with ImageJ software. C: Control. TR: 
Transfection Reagent. Scr: Scrambled non-targeting siRNAs.  
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Figure 4.5: Analysis of HIF-1 and HIF-2 protein expression in hypoxic 
MDA-MB-468 cells following 50nM siRNA treatment. Immunoblots of (i) HIF-
1 and (ii) HIF-2 protein expression after HIF-1 and HIF-2 knockdown with 
50nM siRNAs following 22 hours exposure acute hypoxia (1% O2) (representative 
of n=1 immunoblots). Protein (30µg) was resolved on SDS-polyacrylamide gels, 
transferred to nitrocellulose and probed with anti-HIF-1 and anti-HIF-2, anti--
tubulin and IR conjugated secondary antibodies. Immunoblotting with -tubulin 
was used to assess equal protein loading (iii). Staining was visualised by LI-COR. 
C: Control. H: Hypoxic. TR: Transfection Reagent. 
 
4.4.3: qRT-PCR optimisation following HIF-1 and HIF-2 knockdown.  
 
qRT-PCR was used in order to assess the impact of HIF-1 and HIF-2 
suppression on glycogene expression in hypoxic MDA-MB-468 cells. Gene 
expression of housekeeping genes β-actin, β2M and RPLP0 were measured by 
qRT-PCR following 22 hours of acute hypoxia (1% O2). This indicated the most 
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stable reference gene for qRT-PCR normalisation (Figure 4.6).  Housekeeper 
genes were reanalysed in this section to account for any impact on gene 
expression following siRNA targeting of HIF-1 and HIF-2. Statistical analysis 
indicated that between control and hypoxic cells, β2M was the most stable gene, 
with an average difference in CT values between control and hypoxic cells of 0.1 
± 1.44. This is opposed to the average difference between control and hypoxic 
CT values in β-actin (0.59 ± 0.83) and RPLP0 (0.23 ± 1.38) (Figure 4.6). 
Therefore, all gene expression in siRNA treated cells was normalised to β2M.   
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Figure 4.6: Assessing the stability of housekeeper genes in MDA-MB-468 
cells following siRNA targeting of HIF-1 and HIF-2. Cells were transfected 
with 50nM scrambled siRNA, HIF-1 siRNA, HIF-2 siRNA or supplemented with 
transfection reagent (TR) for a total of 46 hours. Cells were exposed to acute 
hypoxia (1% O2) for 22 hours and harvested on ice. CT values of housekeeping 
genes β-actin, β2M and RPLP0 were determined by qRT-PCR and indicated the 
stability of each gene when subject to different siRNA and oxygen treatments 
(n=3 biological replicates).  
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4.4.4: HIF-1 siRNAs inhibit HIF-1 mRNA expression.  
 
Following transfection with HIF-1 and HIF-2 siRNAs in hypoxic MDA-MB-468 
cells, qRT-PCR was used to establish the effects of HIF-1 and HIF-2 siRNA 
treatment on the mRNA expression of HIF-1, HIF-2 and their respective 
downstream targets CA9 and EPO (Figure 4.7A). 
A reduction in HIF-1 and HIF-2 mRNA expression was observed when cells 
were treated with a non-targeting scrambled siRNA compared to untreated cells, 
but this was not significant (p=0.1688 and 0.8803 respectively). Analysis 
indicated that HIF-1 expression was significantly reduced with HIF-1 siRNA 
treatment (p=0.0005) (Figure 4.7A). Although HIF-1 siRNAs did successfully 
reduce the mRNA expression of HIF-1, it may not have been specific. This is 
due to observation that HIF-2 expression was also significantly (p<0.0001) 
suppressed with HIF-1 siRNAs (Figure 4.7A). 
Surprisingly, HIF-2 siRNAs did not supress the expression of HIF-2 mRNA 
(p=0.9909) but did significantly reduce HIF-1 mRNA (p<0.0001) – indicating that 
the published HIF-2 siRNAs may not have been entirely selective to HIF-2 
mRNA (Figure 4.7A).  The HIF-2 siRNAs used in this study have previously 
been used to suppress HIF-2 expression in normoxic clear cell renal cell 
carcinoma cells, and have demonstrated specificity to HIF-2, however, HIF-2 
siRNA treatment was not performed on a TNBC cell line (Pawlus, Wang and Hu, 
2014).  Furthermore, it is important to note that mRNA stability and protein 
turnover are different in both transcription factors and therefore, it is likely that the 
molecules are controlled in other manners (Marxsen et al., 2004; Galbán and 
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Gorospe, 2009). This may account for the selective suppression of the HIF 
proteins but the non-selective nature of the siRNA molecules on mRNA 
expression.  
CA9 contains a single HRE element that is essential for its transcriptional 
increase during hypoxia and it is one the best characterised targets of HIF-1 
(Pastorekova, Parkkila and Zavada, 2006).  Evidence in the literature is not 
present to indicate CA9 is under the transcriptional regulation of HIF-2. As 
indicated in figure 4.7A, CA9 was knocked down, yet whilst marked it was not 
statistically significant (2-way ANOVA with Tukey’s multiple comparisons) with 
HIF-1 siRNAs (p=0.5058), and unexpectedly, was significantly downregulated 
by HIF-2 siRNAs (p=0.0148). This may indicate that HIF-2 siRNAs were not 
exactly specific to HIF-2, as HIF2 siRNA treatment also impacted on HIF-1 
target gene expression. EPO is less selective with regards to its transcriptional 
upregulation, with reports of regulation by both HIF-1 and HIF-2 (Semenza and 
Wang, 1992; Rankin et al., 2007). However, EPO is thought to be dominantly 
dependent on HIF-2 rather than HIF-1 (Rankin et al., 2007). This correlates 
with the data found here which indicates a significant reduction in EPO 
expression (p<0.0001) when treated with HIF-2 siRNAs (Figure 4.7A).  
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Figure 4.7A: Specificity of siRNA treatment on HIF-1, HIF-2 and 
downstream target gene expression. The relative mRNA expression of HIF-
1, HIF-2 and their respective downstream targets: CA9 and EPO following 
transfection with non-targeting scrambled, HIF-1 or HIF-2 siRNAs. qRT-PCR 
values are shown as mean ± SEM (n=3 biological replicates) and were 
normalised to the housekeeper gene β2M and was analysed with Sabiosciences 
software v2.3 and Graphpad Prism 7. 
 
4.4.5: O-glycan initiating genes GALNT6 and GALNT12 may be regulated by 
HIF-1 in hypoxic MDA-MB-468 cells.  
 
In Chapter 3, HIF-1 and HIF-2 expression correlated with O-glycan initiating, 
glycan extension and sialidase genes. To establish this link, expression of the 
selected glycogenes in hypoxic MDA-MB-468 cells treated with HIF-1 and HIF-
2 siRNA and measured by qRT-PCR. 
Unexpectedly, the mRNA expression of O-glycan initiating genes: GALNT3, 
GALNT7 and GALNT14 was significantly altered by non-targeting scrambled 
siRNAs (p=0.0164, 0.0021 and <0.0001, respectively) (Figure 4.7B). As a result, 
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the significant reduction in expression of GALNT3 and GALNT14 following HIF-
1 siRNA treatment was unable to be attenuated directly due to HIF-1 
suppression (Figure 4.7B).  
Knockdown of HIF-1 did however, result in a significant reduction in GALNT6 
(p=0.0007) and GALNT12 expression (p=0.0269) which were unaffected by the 
scrambled control. This suggests that GALNT6 and GALNT12 expression may 
be regulated by HIF-1. Knockdown of HIF-2 did not alter the expression of any 
of the GALNT O-glycan initiating genes tested and expression was comparable 
to the control cells (Figure 4.7B). GALNT14 did show significantly suppression 
with HIF-2 siRNAs (p=0.0430), however expression was also significantly 
suppressed by the scrambled control (p<0.0001).  
 
 
Figure 4.7B: Analysis of O-glycan initiating gene expression following 
siRNA suppression of HIF-1 and HIF-2. The relative mRNA expression of 
O-glycan initiating genes: GALNT3, 6, 7, 12, 14 and L5 following transfection with 
non-targeting scrambled, HIF-1 or HIF-2 siRNAs. qRT-PCR values are shown 
as mean ± SEM (n=3 biological replicates) and were normalised to the 
housekeeper gene β2M and was analysed with Sabiosciences software v2.3 and 
Graphpad Prism 7. 
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4.4.6: Expression of glycan extension genes B3GNT2 and B4GALT3 are 
significantly altered by HIF-1 suppression.  
 
The mRNA expression of glycan-extension genes: B3GNT2, B4GALT2, 
B4GALT3 and sialidase genes NEU1 and NEU3 were analysed by qRT-PCR in 
hypoxic MDA-MB-468 cells. This was in order to determine the effects of HIF-1 
and HIF-2 suppression on varying arms of the glycosylation process.  
Unexpectedly, the non-targeting scrambled siRNA treatment significantly 
suppressed the expression of B4GALT2, NEU1 and NEU3 in hypoxic cells; 
indicating that the siRNA transfection process itself caused altered glycogene 
expression (Figure 4.7C). However, the expression of B3GNT2 and B4GALT3 
was unaffected by the scrambled siRNAs suggesting that the results presented 
here are valid.  
Suppression of HIF-1 resulted in a significant reduction in expression of glycan 
extension genes B3GNT2 (p=0.0388) and B4GALT3 (p=0.0044). A reduction in 
the relative expression of B4GALT2 was also observed compared to control cells, 
however due to the significant reduction in mRNA expression caused by the 
scrambled control, it cannot be confirmed that this suppression of B4GALT2 was 
entirely due to HIF-1 siRNA treatment. HIF-2 suppression did not significantly 
alter the expression of B3GNT2, B4GALT2 or B4GALT3.  
qRT-PCR analysis of sialidase genes NEU1 and NEU3 indicated that HIF-1 
suppression significantly reduced the expression of NEU3 (p=0.0004). This was 
also observed with HIF-2 siRNA treatment (p=0.0225). However, due to the 
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effects of the scrambled control, this cannot be reported as exclusively the result 
of HIF-1 or HIF-2 suppression (Figure 4.7C).  
 
 
Figure 4.7C: Analysis of Glycan-extension and sialidase gene expression 
following siRNA suppression of HIF-1 and HIF-2. The relative mRNA 
expression of glycan extension genes: B3GNT2, B4GALT2, B4GALT3 and 
sialidase genes NEU1 and NEU3 following transfection with non-targeting 
scrambled, HIF-1 or HIF-2 siRNAs. qRT-PCR values are shown as mean ± 
SEM (n=3 biological replicates) and were normalised to the housekeeper gene 
β2M and was analysed with Sabiosciences software v2.3 and Graphpad Prism 
7. 
 
These results taken together indicate HIF-1 has a significant impact on the gene 
expression of glycan-extension genes: B3GNT2 and B4GALT3, and that these 
genes may be regulated by HIF-1 expression. This further implies that these 
glycan-extension genes may aid in the HIF-1 dominant adaptions to hypoxia in 
TNBC cells.  
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4.5: Discussion  
 
4.5.1: Correlation between HIF and glycogene expression.  
 
Aberrant protein glycosylation is common in TNBC (Hanahan and Weinberg, 
2011) and the work undertaken in this study has elucidated numerous glycogenes 
with altered expression in hypoxic MDA-MB-468 cells. In TNBC, the primary 
metabolic substrate is shifted from glutamine to glucose (Liberti and Locasale, 
2016) due to the adaptations to intra-tumoural hypoxia (Semenza, 2000a). This 
has an impact on DNA, protein and lipid synthesis, ultimately affecting the 
availability of intracellular nucleotide sugars (Liberti and Locasale, 2016). 
Nucleotide sugar availability, coupled with altered glycogene expression has the 
potential to modify the glycan structures on the cell surface (Shirato et al., 2011) 
which can affect cellular attachment, invasion and promote a more aggressive 
tumour phenotype (Varki, 2009).  
Triple negative breast cancer is inherently hypoxic (Vaupel, 2008; Semenza, 
2016) and in this study, TNBC has been shown to preferentially express HIF-1 
in vivo, but HIF-2 in vitro. Others have shown that MDA-MB-468 cells both 
express HIF-1 and HIF-2 protein (Christine Blancher et al., 2000). HIF-1 and 
HIF-2 activity impacts cellular metabolism and the glycolytic cycle (Masoud and 
Li, 2015). However, evidence is not present to suggest that either HIF subunit 
may correlate with the expression of genes involved in glycosylation, in TNBC. 
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4.5.2: siRNA treatment effects on HIF-1 and HIF-2 protein expression. 
 
In order to assess the impact of suppressed HIF-1 and HIF-2 on glycogene 
expression, expression of HIF- subunits were inhibited with siRNA treatment.  
HIF-1 and HIF-2 siRNAs moderately suppressed HIF-1 and HIF-2 protein 
expression at a concentration of 50nM in hypoxic MDA-MB-468 cells (Figure 4.5). 
Absolute knockdown of either HIF-α protein was not achieved and is perhaps a 
result of either inefficient transfection, which would be overcome via the use of a 
positive siRNA transfection control, or due to saturation of the endogenous RNAi 
pathway. 
Interestingly, where HIF-1 was suppressed by HIF-1 siRNA treatment, HIF-2 
protein expression in hypoxic cells appeared to increase (Figure 4.5). Studies 
employing the siRNA used here have assessed HIF1- and HIF-2 expression 
however, cross-regulation was not found at the protein level (Pawlus, Wang and 
Hu, 2014). Although, others have analysed HIF-1/HIF-2 cross-regulation at the 
mRNA level in neuroblastoma cell lines SK-N-BE(2)c and KCN-69n, where 
knockdown of HIF-1 enhanced the expression of HIF-2 and vice versa 
(Hamidian et al., 2015). Alternatively, the apparent cross-regulatory mechanism 
identified here may be as a result of the endogenous HIF-1α antisense transcript 
in which during prolonged (>12h) periods of hypoxia, HIF-1α can become 
regulated by autonegative feedback either by itself, or through trans-regulatory 
mechanisms between HIF-1α and HIF-2α (Uchida et al., 2004). 
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4.5.3: HIF-2 suppression significantly decreased mRNA expression of the 
HIF-1 target gene, CA9.  
 
It was surprising that potential cross regulation was observed, however this may 
have been a result of off-targeting effects. siRNAs bind several target mRNAs 
and share full mRNA sequence complementarity with their intended targets 
(Elbashir, Lendeckel and Tuschl, 2001). siRNAs trigger enzymatic cleavage of 
their matched mRNA however, off-target activity can occur; often due to the 
technology they are delivered by or by certain properties of the siRNA itself (Chi 
et al., 2003; Semizarov et al., 2003). It could be suggested that off-targeting 
effects occurred which resulted in the knockdown of HIF-2 mRNA with HIF-1 
siRNAs because HIF-1 and HIF-2 share similar domain structure (Figure 4.8A) 
(Holmquist-Mengelbier et al., 2006).  siRNA treatment used here consisted of one 
siRNA sequence which may account for potential inefficiency of HIF-2 
knockdown this targeted the HIF-2 coding sequence from approximately 600bp 
to 1200bp (Figure 4.8).  This opposes now conventional methods of 4 siRNA 
sequences pooled together.  
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Figure 4.8: Targeting region of HIF-2 siRNAs used in this study. siRNAs 
targeted the coding region of the HIF-2 transcript at approximately 600bp to 
1200bp which is indicated in yellow. Figure adapted from Qiagen GeneGlobe 
Specification (2019).  
 
One of the best characterized targets of HIF-1 is carbonic anhydrase 9 (CA9). 
Interestingly, CA9 expression was not significantly affected by the partial 
knockdown of HIF-1, but HIF-2. In other studies, CA9 expression has 
remained unaffected by HIF-2 siRNA treatment, in MDA-MB-231 cells (Pawlus, 
Wang and Hu, 2014). Current literature does not describe HIF-2 mediated 
transcriptional regulation of CA9; therefore, it remains unclear as to why a 
decrease in HIF-2 significantly decreased CA9 mRNA expression. In order to 
better investigate and determine if HIF-2 suppression also impacted HIF-1 
downstream genes; the expression of additional HIF-1 downstream target 
genes should be assessed, such as LDHA, GLUT1 and GLUT3 (Chen et al., 
2001).  Furthermore, it would be of interest to assess the protein expression of 
CA9 following HIF-1 and HIF-2 siRNA treatment, thus, determining if 
suppression of CA9 by HIF-2 siRNAs only occurred at the mRNA level.   
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Figure 4.8A: Domain structure of HIF-1 and its mRNA percentage 
homology with HIF-1. Potential function of the domains is indicated outside of 
brackets. bHLH: basic helix-loop-helix. PAS: PER-ARNT-SIM. ODD: oxygen-
dependent degradation. TAD-N: Transacting domain N-terminal. TAD-C. 
transacting domain C-terminal. Figure adapted from (Hong, Lee and Kim, 2004; 
Koh and Powis, 2009).  
Unexpectedly, HIF-2 siRNA treatment did not significantly decrease HIF-2 
mRNA expression. However, EPO (a downstream gene predominantly regulated 
by HIF-2) was significantly downregulated which suggests that HIF-2 
transcription was in fact reduced in this model under the conditions employed 
here.  
 
4.5.4: HIF-1 promotes expression of B3GNT3, B4GALT3, GALNT6 and 
GALNT12 in hypoxic MDA-MB-468 cells. 
 
Protein glycosylation is recognised to be one of the most important post 
translational modifications in mammalian cells, however the process is one of the 
most complex to study (Varki, 2009). Changes to glycan structures is believed to 
occur early during malignant transformation (Munkley and Elliott, 2016) and it has 
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been shown (Chapter 3, and by others), that expression of glycosylation genes 
are significantly altered in TNBC compared to non-cancerous tissue (Potapenko 
et al., 2010). In addition to altered glycogene expression (Albuquerque et al., 
2018), TNBCs are known to be inherently hypoxic and express HIF-1 and HIF-
2 (Semenza, 2016). 
Partial knockdown of HIF-1 significantly reduced the relative mRNA expression 
of glycan extension genes: B3GNT2, B4GALT3, and O-glycan initiating genes:  
GALNT6 and GALNT12. B4GALT1 is closely related to B4GALT3 with a similar 
glycosylation function and has been linked to increased aggression in clear cell 
renal carcinoma (Xie et al., 2016). However, there is little evidence in the literature 
to suggest that B3GNT2 or B4GALT3 promote aggressive tumour growth in 
TNBC (Potapenko et al., 2010). From the evidence presented here, it is 
suggested that B3GNT2 and B4GALT3 may be under the transcriptional control 
of HIF-1 in hypoxic MDA-MB-468 cells. Therefore, it may be involved in 
facilitating the aggressive tumour phenotype associated with overexpression of 
HIF-1 (Jin et al., 2016).   It could be hypothesised that overexpression of glycan 
extension genes B3GNT2 and B4GALT3 due to HIF-1 may result in a high 
proportion of poly-N-acetyllactosamine chains. Tumour cells that are decorated 
with newly synthesised poly-N-acetyllactosamine chains are known to facilitate 
cell-cell interaction and increase metastasis through lectins such as P- and E-
selectins  (Nonaka and Fukuda, 2016).  
O-glycan initiating genes GALNT6 and GALNT12 have been shown to be 
upregulated in breast cancer, but not specifically TNBC (Potapenko et al., 2010). 
GALNT6 suppression in T47D BrCa cells resulted in enhanced cell adhesion and 
reduced growth of BrCa cells, thus implying GALNT6 promotes cell mobility (Park 
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et al., 2010). However, T47D is not a TNBC BrCa cell line, so it is not possible to 
directly relate GALNT6 with increased cell metastasis in TNBC. Similarly, 
evidence that directly relates HIF-1 and GALNT6 expression is not present in 
the literature; therefore, the data presented here is the first time that decreased 
GALNT6 and GALNT12 expression has been reported due to knockdown of HIF-
1 in TNBC cells. These findings would imply that in TNBC, a high proportion of 
Tn antigen is expected to be expressed, due to the overexpression of GALNT6 
and GALNT12. Therefore, the suppression of HIF-1 should result in decreased 
expression of GALNT6 and GALNT12 which will in turn, decrease the expression 
of Tn antigen. As the Tn antigen is known to facilitate tumour metastasis (Ju et 
al., 2013) due to alterations in cell-cell interactions, signal transduction and 
increased immune evasion (Bapu et al., 2016), decreasing the expression of Tn 
antigen should improve TNBC patient outcomes.  
These results taken together suggest: B3GNT2, B4GALT4, GALNT6 and 
GALNT12 may be regulated by HIF-1 in TNBC. This is the first time this has 
been reported to our knowledge. 
 
4.5.5: HIF-1/HIF-2 cross-regulatory mechanism.  
 
In the literature, there are reports of HIF-1/HIF-2 redundancy. HIF-1 is the 
main coordinator of genes encoding enzymes involved in glycolysis such as 
phosphofructokinase (PFK) and lactate dehydrogenase (LDHA), carbonic 
anhydrase 9 (CA9) and BCL2/adenovirus E1B interacting protein 3 (BNIP3) 
(Keith, Johnson and Simon, 2011). These genes are involved in various 
processes including pH regulation and apoptosis (Keith, Johnson and Simon, 
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2011). HIF-2 contrastingly prompts the induction of genes such as matrix 
metalloproteinases (MMP) 2, and 13; genes that are involved in cellular invasion 
(Warnecke et al., 2004). However, the regulation of glycolytic enzymes has also 
attributed to HIF-2 in the absence of HIF-1 (Warnecke et al., 2004; 
Scortegagna et al., 2005). Moreover, HIF-1 has shown abilities in activating 
selected MMPs (Fujiwara et al., 2007).  
In murine models, targeted deletion of HIF-1 or HIF-2 subunits resulted in 
lethal phenotypes that die in utero (Franke et al., 2013). However, in HeLa cells, 
HIF-1 and HIF-2 target gene specificity has been overcome by forced 
expression of HIFα subunits (Warnecke et al., 2004).  Overexpression of the HIF 
subunits can also occur through tumorigenic events which affect the HIF/pVHL 
(von-Hippel Lindau tumour suppressor) in which it has been suggested that the 
two genes were performing similar functionals with little or no effect on the 
biological phenotype (Figure 4.9) (Warnecke et al., 2004). This implies that both 
HIF subunits can substitute the other subunits specific functions under some 
circumstances. 
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Figure 4.9:  Schematic illustrating loss of HIF target gene due to altered 
HIF/pVHL system in cancer. Each HIF- subunit shows high affinity to hypoxia 
response elements of its intended target genes in mammalian cells with functional 
HIF/pVHL. Overexpression of HIF- subunits though tumourigenic events may 
affect the HIF/pVHL system leading to loss of target gene specificity (Warnecke 
et al., 2004).  
 
In this study, knockdown of HIF-2 appeared to increase the expression of HIF-
1 protein (Figure 4.4) and furthermore, knockdown of HIF-1 mRNA appeared 
to decrease HIF-2 expression (Figure 4.8). This proposes that HIF-2 
expression may rely on HIF-1 and in the absence of HIF-2: HIF-1 may 
compensate. This evidence adds to the suggestion that on occasion, there may 
be cross-regulatory mechanisms between the HIF transcription factors. This may 
be due to the above-mentioned overexpression of either subunit due to 
tumourigenesis, or due to several other factors.   
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HIF-1 is predominantly regulated by VHL-mediates proteasomal degradation, 
however several studies have elucidated how it can be regulated by other post-
transcriptional mechanisms (Galban et al., 2008). RMB38 is an RNA-binding 
protein and target of the p53 family, which regulates gene expression through 
mRNA stability and translation (Zhang et al., 2011). RMB38 has been shown to 
regulate HIF-1 expression through mRNA translation under hypoxia (Cho et al., 
2015). HCT116 cells treated with CoCl2, a chemical inducer of hypoxia (Piret et 
al., 2002), demonstrated that RMB38 overexpression decreased HIF-1 protein 
and knockdown of RMB38 resulted in increased expression of HIF-1 protein 
(Cho et al., 2015), thus, suggesting that RMB38 is a transcriptional regulator of 
HIF-1 under hypoxia. In this study, HIF- mediated mRNA regulation through 
mechanisms such as RMB38 may have factored into the cross-regulation 
observed between HIF-1 and HIF-2.   
 
4.5.6: Conclusions and future work  
 
The work undertaken in this chapter aimed to knockdown the expression of HIF-
1 and HIF-2 in hypoxic MDA-MB-468 cells and elucidate if the suppression of 
HIF-1/HIF-2 results in altered expression of genes involved in protein 
glycosylation. In doing so, a greater understanding of the mechanisms by which 
hypoxia inducible factors regulate cell glycosylation has been gathered and 
potential biomarkers of disease have been identified. The possible identification 
of genes that are altered in expression as a result of the loss of HIF-1 or HIF-
2 in hypoxic TNBC cells found here is novel and adds to the growing body of 
evidence that inter-tumoral hypoxia influences many aspects of cell glycosylation. 
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This provides evidence that hypoxic MDA-MB-468 cells may show differentially 
expressed glycogenes including: B3GNT2, B4GALT3, GALNT6 and GALNT12 
as a result of the suppression of HIF-1. This indicates that there may be 
signalling link between HIF-1 and these genes, which potentially aid in the 
tumour phenotype associated with HIF-1 expression in TNBC. However, further 
work is required to elucidate exactly which aggressive tumour traits are attributed 
to which glycogene due to HIF-1.  
 
4.5.6.1: siRNA treatment considerations: Cell passage number.  
 
In this investigation cells were at approximately passage 30-35. Cells of this age 
may have been subject to cell senescence and therefore may not have 
responded to siRNA treatment with the same intensity of  younger cells (Rubin, 
1997).  The manufacture’s recommendations state that cells with high passage 
number are prone to change their growth behaviour and morphology and can be 
less susceptible to transfection (HiPerfect Transfection Handbook, 2010).  
Unfortunately, due to time restraints the passage number of the cells used in the 
siRNA experiments were unable to be performed at a lower passage.  
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4.5.6.2: siRNA treatment considerations: Investigating potential off-
targeting siRNAs.  
 
The HIF-1 downstream target CA9 was significantly suppressed by HIF-2 
siRNA treatment. In order to understand if this was an off-target effect, future 
experiments should include alternative HIF-1 downstream targets, such as 
GLUT1, GLUT3 or LDHA (Semenza, 2000). This will indicate whether HIF-2 
siRNA is indeed affecting HIF-1 expression and subsequent HIF-1 
downstream targets, which was thought to occur in the results documented in 
section 4.4.4.  
It is also important to acknowledge that the siRNA knockdown implemented 
throughout this study did not result in absolute knockdown of the target proteins. 
This is assumed to be as a result of poor siRNA specificity or suboptimal 
transfection efficiency. In future experiments, it is recommended that further 
transfection titrations are performed to identify optimal doses of siRNA and 
transfection reagent   
 
4.5.7: Future experiments; HIF suppression and the binding of biotinylated 
lectins.  
 
As documented in Chapter 3, biotinylated lectins can be used to establish the 
effect of hypoxia on cell surface glycans and the proportion of several sugar 
residues on the surface of TNBC cells. It would of great interest to repeat these 
investigations with cells transfected with HIF-1 and HIF-2 siRNAs to compared 
to sugar residues of HIF-1/HIF-2 positive cells and those treated with siRNAs. 
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This would indicate whether the suppression of HIFs influence the expression of 
glycans on the cell surface and ultimately; cell glycosylation. Insight would be 
gathered into the cell glycocalyx of hypoxia MDA-MB-468 cells and determine the 
impact of HIF and HIF suppression on TNBC aggression due to the potential 
alterations observed ie. truncated and over-extended glycans.   
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Chapter 5: General discussion, study limitations and future 
directions. 
 
5.1: Glycogene expression is altered in TNBC and these changes are also 
found in hypoxic TNBC cells.  
 
In Chapter 3, array profiling of tumour samples 11004 and 10046 elucidated a 
marked change in the glycosylation profile between TNBC and tissue matched 
controls. Similar trends of altered gene expression among glycan-extension, O-
glycan initiating, N-glycan branching, sialidase and sialyltransferase families was 
observed between three TNBC tumours. This provided an answer to the first 
research question proposed: the glycogene expression profile of TNBC does in 
fact differ to tissue matched samples. These findings add to the growing body of 
literature and provide further evidence that glycosylation gene expression is 
altered in TNBC malignancies (Potapenko et al., 2010; Chen et al., 2016). 
 
5.2: The glycan profile of MDA-MB-468 cells is altered in response to acute 
hypoxia.  
 
Hypoxia has the potential to significantly alter cell metabolism and gene 
expression (Semenza, 2012); therefore, it has the potential to alter hypoxic TNBC 
tumour glycosylation. In Chapter 3, the degree of hypoxia inducible factor 
induction was measured via qRT-PCR in TNBC tumour samples. HIF-1 was 
preferentially expressed in all three TNBC tumours, whereas HIF-2 was 
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unanimously downregulated. Hypoxic MDA-MB-468 cells were used as a cellular 
model of TNBC, both HIF-1 and HIF-2 protein expression was observed, 
confirming both HIF- pathways are activated by acute hypoxia in TNBC (Koh et 
al., 2011).  
Following TNBC tumour glycogene expression profiling and validation in hypoxic 
TNBC cells, lectin analysis of hypoxic MDA-MB-468 cells indicated that hypoxia 
potentially influences the binding of some lectins to cell surface glycans. This was 
uncovered through differential binding of lectins: PNA, PHA-E and LCA, which 
suggested hypoxia increases the proportion of complex N-type glycans, non-
reducing terminal β-D-galactose, core fucosylated glycans and N-acetyl-
neuraminidase residues on the surface of MDA-MB-468 cells.  These findings 
answered the third question proposed in this chapter: that the glycan profile of 
hypoxia MDA-MB-468 cells is altered in response to acute hypoxia. These results 
were significant as this type of lectin analysis provided novel information to the 
alterations of sugar moieties found on the surface of TNBC cells following hypoxic 
exposure. Furthermore, indicating that hypoxia does cause significant changes 
to cell surface glycosylation. This has wider implication and demonstrates that 
the hypoxic tumour environment has the ability to significantly impact cell-cell 
interactions and potentially facilitate cell metastasis, invasion and promote a 
more aggressive tumour phenotype.  
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5.3: HIF-1 and HIF-2 protein expression was suppressed by siRNA 
treatment.  
 
In Chapter 3, qRT-PCR validation identified that HIF-1 expression correlated 
with the expression of glycogenes: GALNT3, GALNT6, GALNT7, GALNT12, 
B3GNT2, B4GALT2, B4GALT3, NEU1 and NEU3. In addition, the expression of 
GALNTL5 correlated with HIF-2 induction in TNBC tumours.  
The correlation between HIF-induction and glycogene expression was 
investigated in Chapter 4, where siRNA gene knockdown was employed targeting 
HIF-1 and HIF-2 in hypoxic MDA-MB-468 cells. Immunoblotting confirmed the 
successful suppression of HIF-1 and HIF-2 protein by their respective siRNA 
treatment. Interestingly, where HIF-1 was suppressed by HIF-1 siRNA 
treatment, HIF-2 protein expression in hypoxic cells appeared to increase. This 
cross-regulation was not found by others using identical siRNAs in TNBC cells 
(Pawlus, Wang and Hu, 2014). Henceforth, this may be the first time that cross-
regulation between HIF-1 and HIF-2 has been observed in hypoxic MDA-MB-
468 cells.  These results may signify that both HIF subunits can substitute each 
other’s specific functions under some circumstances.  
 
5.3.1: B3GNT2, B4GALT3, GALNT6 and GALNT12 are downregulated when 
HIF-1 is suppressed in hypoxic TNBC cells.  
 
Knockdown of HIF-1 significantly reduced the relative mRNA expression of 
glycan extension genes: B3GNT2, B4GALT3, and O-glycan initiating genes:  
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GALNT6 and GALNT12. This indicated that there is a link between HIF-1 
signalling and these genes, which potentially aids in the tumour phenotype 
associated with HIF-1 expression in TNBC. Additionally, these findings 
answered to the second research question of this chapter: the knockdown of HIF-
1 in hypoxic MDA-MB-468 cells alters expression of O-glycan initiating and 
glycan-extension gene expression. This is the first time that this has been 
reported in the literature and signifies a significant insight into the cellular glycome 
alterations in TNBC due to hypoxic adaptation.   However, further work is required 
to elucidate exactly which aggressive tumour traits are associated with altered 
glycogene expression.  
The role of HIF-2 in regulating glycogene expression in TNBC is still unclear as 
glycogene expression was also affected by control siRNA. However, based on 
initial observations, HIF-1 seemed to predominantly have a greater impact on 
glycogene expression in TNBC. This implies glycogene expression in hypoxic 
TNBC cells seems to correlate with the HIF-1 arm of the hypoxic adaptation 
machinery.  Furthermore, altered glycosylation in hypoxic tumours may aid in 
promoting the key hallmarks of cancer including evading the immune response, 
invasion and metastasis (Hanahan and Weinberg, 2011).  
 
5.4: Future directions.  
 
Initially, this thesis broadly explored altered glycosylation gene expression in 
TNBC samples, compared to adjacent non-cancerous tissues. Several 
glycogenes were altered compared to healthy breast tissue, thus providing novel 
information regarding altered glycogene expression in TNBC. Future work should 
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include increasing the sample size of tumours profiled compared to patent 
matched, control tissue for greater statistical significance. Obtaining greater 
information on tumour stage, patient race, age and body mass index (BMI) would 
also be essential to correlate changes in gene expression with tumour stage and 
grade. This would indicate changes in glycogene expression with patient race 
and therefore susceptibility to TNBC. Interestingly, a higher proportion of obese 
patients are likely to suffer from TNBC, gathering data on patient BMI would allow 
for correlation of this data (Trivers et al., 2009).  
It would also be of interest to investigate other groups of glycogenes as this thesis 
focused mainly on the validation of altered expression of O-glycan initiating and 
glycan-extension genes. Analysing altered glycogene expression from N-glycan 
branching genes, sialyltransferases, fucosylases and other glycan decorating 
genes would provide a well-rounded dataset regarding how breast tissue 
becomes altered during malignancy due to the hypoxic tumour environment. 
Gathering further data would allow for identification of potential biomarkers of 
tumour progression and therefore allow for the development of new targeted 
treatments for this devastating subtype of breast cancer.  
 
5.4.1: Does altered glycogene expression translate into altered tumour 
glycosylation profile? 
 
The original aim of the project was to confirm that the observed changes in gene 
expression in TNBC correlated with altered glycan expression profile in hypoxic 
TNBC. This was to be achieved via immunohistochemistry (IHC) using paraffin-
embedded formalin-fixed (PPFE) tissue sections. Altered biotinylated lectin 
159 
 
staining would be correlated with markers of hypoxia (CA9) to confirm the change 
was associated with hypoxia.  This would have helped to distinguish subtle 
alterations in cellular glycosylation, as lectin IHC can be used to identify 
glycosylation changes that can aid cellular transformation to malignancy and 
tumour progression (Zhou et al., 2015).   
This knowledge that would aid the understanding of how sugar attachment occurs 
in response to the hypoxic tumour microenvironment. However, availability of the 
samples from the tissue bank meant sections could not be analysed.  Undertaking 
this analysis would be essential so that a stronger biochemical understanding of 
how cancerous glycosylation occurs in TNBC. This would be achieved correlating 
positive staining of hypoxia markers in PFFE sections with altered glycogene 
expression. 
 
5.4.2: Investigating the effects of suppressed HIF-1 and HIF-2 on sugar 
residue proportions on hypoxic MDA-MB-468 cells.  
 
Future work will also address some of the shortcomings of this research due to 
time restraints of the MRes including analysis of the lectin binding profile in 
hypoxic MDA-MB-468 cells with suppressed HIF-1 or HIF-2 expression (by 
siRNA treatment). Therefore, the impact of HIF-1 or HIF-2 suppression on the 
expression of complex N-type glycans, core fucosylated glycans, non-reducing 
terminal β-D-galactose and N-acetyl-neuraminidase residues on the cell surface 
of hypoxic TNBC cells will be determined. This research would confirm observed 
changes in gene expression with physical changes in the glycosylation profile of 
TNBC.  
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In Chapter 3, lectin binding analysis showed minimal DBA binding to hypoxic 
MDA-MB-468 cells compared to control cells. DBA binds terminal N-
acetylgalactosamine (GalNAc) residues and the lack of DBA binding was 
hypothesised to be a result of decreased expression of: GALNT6, GALNT7, 
GALNT12 and GALNT14, genes involved in adding the first GalNAc residue to 
initiate O-glycans. Furthermore, decreased B4GALT2 and B4GALT3 expression 
in hypoxic MDA-MB-468 cells may have influenced the lack of PNA lectin binding. 
PNA binds to galactose and B4GALT2 and B4GALT3 enzymes catalyse the 
addition of galactose residues to glycans (Mérant et al., 2005). Therefore, if 
galactose addition is diminished during glycan synthesis due to decreased 
B4GALT2/3 expression - a lack of PNA binding in TNBC would be expected.  
In Chapter 4, suppression of HIF-1 significantly decreased GALNT6, GALNT12, 
B3GNT2 and B4GALT3 expression following hypoxia. In hypoxic MDA-MB-468 
cells with suppressed HIF-1, it would be expected to see a significant decrease 
in PNA and DNA binding. This is due to the decreased enzymatic addition of 
GalNAc and galactose. This implies HIF-1 plays a role in increasing GalNAc 
and galactose glycosylations on the cell surface of hypoxic MDA-MB-468 cells. 
An increase in GalNAc residues is associated with expression of the Tn antigen. 
Tn antigen expression is strongly associated with poor prognosis and tumour 
metastasis in BrCa (Ju et al., 2013) due to altered cell-cell interactions, signal 
transduction and immune evasion (Bapu et al., 2016) (Figure 5.1). Numerous 
alterations to protein glycosylations have been tied to correlations in tumour 
grade, increased metastasis and invasion. Often, altered glycan expression is 
correlated with poor patient prognosis (Kim and Varki, 1997). Identifying the 
glycogenes which have a direct impact on tumour cell invasion, metastasis and 
immune system invasion could be used as a potential drug target to improve 
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patient prognosis through new treatment options. If successful, targeting altered 
glycans could be used in other types of breast cancers and hypoxic tumours. 
Potentially, similar examples of aberrant glycosylation may be found in other 
hypoxic tumours and may correlate with tumour stage.  
 
 
Figure 5.1: Altered cell adhesion, immune-evasion and increased cell 
metastasis in TNBC due to Tn/STn-antigen expression. STn/Tn antigens are 
tumour-associated markers that are absent in normal, non-malignant tissues. As 
a result of defective glycan extension by enzymes such as B3GNT2 and 
B4GALT3; Tn antigen or STn antigen is expressed resulting in a more aggressive 
tumour phenotype. Figure adapted from (Ju et al., 2013).   
 
5.4.3: siRNA experiments.  
 
During experiments where siRNAs were used, siRNA scrambled controls caused 
expression of several genes to change.  Upon repetition of this experiment, it 
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would be suggested to use the cells at a lower passage; as recommended by the 
manufacturer’s instructions. If siRNA controls persisted to cause unexpected 
changes in gene expression, a different siRNA scrambled control should be used. 
As the control siRNAs used in these experiments were designed to have no 
known mRNA targets in the cell used, it is unlikely that they caused knockdown 
of the genes in question and it was the addition of the siRNA itself that caused 
knockdown by other means. To improve the reliability of the results, fresh aliquots 
of siRNAs, transfection reagents and newly thawed cells should be used after 
they have been passaged at a minimum of three times to recover from thawing. 
 
5.4.4: Is glycosylation impacted by the degree hypoxia at different 
timepoints? 
 
This research focused on the changes to protein glycosylation in TNBC when 
exposed to hypoxia (1% O2) after 22 hours of exposure. Several studies have 
investigated the effects of hypoxia at different lengths of exposure and oxygen 
percentage and have found varying results (Shirato et al., 2011). It has been well-
established that differences in the hypoxia response are due to the severity of 
hypoxia, the timeframe of hypoxic exposure and that HIF-1 and HIF-2 may be 
involved at different points of the adaptive response (Keith, Johnson and Simon, 
2011). As glycosylation is a successive and hierarchal process (Burchell et al., 
2018) it may be possible that varying degrees of hypoxia and the length of 
hypoxia duration may affect how protein glycosylation is impacted.  It would be of 
interest to repeat the experiments in this thesis with varying hypoxic conditions 
including <0.1% O2 and timepoints of 12, 48 and 72 hours of exposure.   
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